<pmc-articleset xmlns:ns0="http://www.niso.org/schemas/ali/1.0/" xmlns:ns1="http://www.w3.org/1999/xlink"><article dtd-version="1.3" id="mol213124" xml:lang="en" article-type="research-article">
  
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Mol Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Mol Oncol</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1878-0261</journal-id>
      <journal-id journal-id-type="publisher-id">MOL2</journal-id>
      <journal-title-group>
        <journal-title>Molecular Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1574-7891</issn>
      <issn pub-type="epub">1878-0261</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">34669238</article-id>
      <article-id pub-id-type="pmc">8936524</article-id>
      <article-id pub-id-type="doi">10.1002/1878-0261.13124</article-id>
      <article-id pub-id-type="publisher-id">MOL213124</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Intrinsic and acquired drug resistance to LSD1 inhibitors in small cell lung cancer occurs through a TEAD4&#8208;driven transcriptional state</article-title>
        <alt-title alt-title-type="right-running-head">Epigenetic resistance mechanisms for LSD1 inhibitors</alt-title>
        <alt-title alt-title-type="left-running-head">W. Yan <italic toggle="yes">et&#8201;al</italic>.</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="mol213124-cr-0001" contrib-type="author">
          <name>
            <surname>Yan</surname>
            <given-names>Wen</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0980-0306</contrib-id>
          <xref rid="mol213124-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="mol213124-cr-0002" contrib-type="author">
          <name>
            <surname>Chung</surname>
            <given-names>Chi&#8208;Yeh</given-names>
          </name>
          <xref rid="mol213124-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="mol213124-cr-0003" contrib-type="author">
          <name>
            <surname>Xie</surname>
            <given-names>Tao</given-names>
          </name>
          <xref rid="mol213124-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="mol213124-cr-0004" contrib-type="author">
          <name>
            <surname>Ozeck</surname>
            <given-names>Mark</given-names>
          </name>
          <xref rid="mol213124-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="mol213124-cr-0005" contrib-type="author">
          <name>
            <surname>Nichols</surname>
            <given-names>Timothy C.</given-names>
          </name>
          <xref rid="mol213124-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="mol213124-cr-0006" contrib-type="author">
          <name>
            <surname>Frey</surname>
            <given-names>Jessica</given-names>
          </name>
          <xref rid="mol213124-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="mol213124-cr-0007" contrib-type="author">
          <name>
            <surname>Udyavar</surname>
            <given-names>Akshata R.</given-names>
          </name>
          <xref rid="mol213124-aff-0002" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="mol213124-cr-0008" contrib-type="author" corresp="yes">
          <name>
            <surname>Sharma</surname>
            <given-names>Shikhar</given-names>
          </name>
          <xref rid="mol213124-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
          <address>
            <email>shikhar.sharma@pfizer.com</email>
          </address>
        </contrib>
        <contrib id="mol213124-cr-0009" contrib-type="author" corresp="yes">
          <name>
            <surname>Paul</surname>
            <given-names>Thomas A.</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6465-886X</contrib-id>
          <xref rid="mol213124-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
          <address>
            <email>thomas.a.paul@pfizer.com</email>
          </address>
        </contrib>
      </contrib-group>
      <aff id="mol213124-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Oncology Research Discovery</named-content>
<institution>Pfizer Worldwide Research and Development</institution>
<city>San Diego</city>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
      <aff id="mol213124-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Arcus Biosciences</institution>
<city>Hayward</city>
<named-content content-type="country-part">CA</named-content>
<country country="US">USA</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break />
T.&#8201;A.&#8201;Paul and S.&#8201;Sharma, Pfizer Oncology Research Unit, 10724 Science Center Drive, San Diego, CA 92121, USA<break />
Tel: +1&#8201;858&#8201;526&#8201;4241 (TAP); +1&#8201;858&#8201;526&#8201;4172 (SS)<break />
E&#8208;mails: <email>thomas.a.paul@pfizer.com</email> (TAP); <email>shikhar.sharma@pfizer.com</email> (SS)<break />
</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>09</day>
        <month>11</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2022</year>
      </pub-date>
      <volume>16</volume>
      <issue seq="70">6</issue>
      <issue-id pub-id-type="doi">10.1002/mol2.v16.6</issue-id>
      <fpage>1309</fpage>
      <lpage>1328</lpage>
      <history>
<date date-type="rev-recd"><day>20</day><month>7</month><year>2021</year></date>
<date date-type="received"><day>02</day><month>4</month><year>2021</year></date>
<date date-type="accepted"><day>19</day><month>10</month><year>2021</year></date>
</history>
      <permissions>
        
        <copyright-statement content-type="article-copyright">&#169; 2021 Pfizer, Inc. <italic toggle="yes">Molecular Oncology</italic> published by John Wiley &amp; Sons Ltd on behalf of Federation of European Biochemical Societies.</copyright-statement>
        <license>
          <ns0:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ns0:license_ref>
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" ns1:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" ns1:href="file:MOL2-16-1309.pdf" />
      <abstract id="mol213124-abs-0001">
        <p>Small&#8208;cell lung cancer (SCLC) is a heterogeneous disease, consisting of intratumoral and intertumoral neuroendocrine (ASCL1 and/or NEUROD1), mesenchymal&#8208;like, and YAP&#8208;driven transcriptional states. Lysine&#8208;specific demethylase 1 (LSD1; also known as KDM1A) inhibitors have recently been progressed to clinical trials in SCLC based on a promising preclinical antitumor activity. A potential clinical limitation of LSD1 inhibitors is the heterogeneous drug responses that have been observed in SCLC cell lines and patient&#8208;derived models. Based on these observations, we studied molecular and transcriptional signatures that predict patient response to this class of drug. Employing SCLC patient&#8208;derived transcriptional signatures, we define that SCLC cell lines sensitive to LSD1 inhibitors are enriched in neuroendocrine transcriptional markers, whereas cell lines enriched in a mesenchymal&#8208;like transcriptional program demonstrate intrinsic resistance to LSD1 inhibitors. We have identified a reversible, adaptive resistance mechanism to LSD1 inhibitors through epigenetic reprogramming to a TEAD4&#8208;driven mesenchymal&#8208;like state. Our data suggest that only a segment of SCLC patients, with a defined neuroendocrine differentiation state, will likely benefit from LSD1 inhibitors. It provides novel evidence for the selection of a TEAD4&#8208;driven mesenchymal&#8208;like subpopulation resistant to LSD1 inhibitors in SCLC patients that may require effective drug combinations to sustain effective clinical responses.</p>
      </abstract>
      <abstract abstract-type="graphical" id="mol213124-abs-0002">
        <p>Here, we identify intratumor and intertumor heterogeneity limits the activity of LSD1 inhibitors in SCLC. Activity of LSD1 inhibitors in SCLC is confided in cells enriched in neuroendocrine transcriptional programs. Transdifferentiation of SCLC into a TEAD4&#8208;driven mesenchymal&#8208;like state represents an acquired resistance mechanism to LSD1 inhibitors. Drug combinations targeting YAP&#8208;TEAD pathways with LSD1 inhibitors may be an effective strategy to target intrinsic&#8208; and adaptive&#8208;resistant populations and sustain effective clinical responses.<boxed-text position="anchor" content-type="graphic" id="mol213124-blkfxd-0001"><graphic ns1:href="MOL2-16-1309-g003.jpg" position="anchor" id="jats-graphic-1" /></boxed-text>
</p>
      </abstract>
      <kwd-group>
        <kwd id="mol213124-kwd-0001">drug resistance</kwd>
        <kwd id="mol213124-kwd-0002">epigenetic therapy</kwd>
        <kwd id="mol213124-kwd-0003">KDM1A</kwd>
        <kwd id="mol213124-kwd-0004">LSD1</kwd>
        <kwd id="mol213124-kwd-0005">small&#8208;cell lung cancer</kwd>
      </kwd-group>
      <funding-group>
        <award-group id="funding-0001">
          <funding-source>
            <institution-wrap>
              <institution>Pfizer
</institution>
              <institution-id institution-id-type="doi">10.13039/100004319</institution-id>
            </institution-wrap>
          </funding-source>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="7" />
        <table-count count="0" />
        <page-count count="1328" />
        <word-count count="10576" />
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>March 2022</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.2 mode:remove_FC converted:21.03.2022</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body id="mol213124-body-0001">
    <def-list list-content="abbreviations" id="mol213124-lp-0001">
      <title>Abbreviations</title>
      <def-item>
        <term>ASCL1</term>
        <def>
          <p>achaete&#8208;scute homolog 1</p>
        </def>
      </def-item>
      <def-item>
        <term>ATAC&#8208;seq</term>
        <def>
          <p>assay for transposase&#8208;accessible chromatin using sequencing</p>
        </def>
      </def-item>
      <def-item>
        <term>BRD4</term>
        <def>
          <p>bromodomain&#8208;containing protein 4</p>
        </def>
      </def-item>
      <def-item>
        <term>CREBBP</term>
        <def>
          <p>cAMP response element&#8208;binding protein&#8208;binding protein</p>
        </def>
      </def-item>
      <def-item>
        <term>EMT</term>
        <def>
          <p>epithelial&#8211;mesenchymal transition</p>
        </def>
      </def-item>
      <def-item>
        <term>EP300</term>
        <def>
          <p>histone acetyltransferase p300 or E1A&#8208;associated protein p300</p>
        </def>
      </def-item>
      <def-item>
        <term>EZH2</term>
        <def>
          <p>enhancer of zeste homolog 2</p>
        </def>
      </def-item>
      <def-item>
        <term>GESA</term>
        <def>
          <p>gene set enrichment analysis</p>
        </def>
      </def-item>
      <def-item>
        <term>GFI1B</term>
        <def>
          <p>growth factor independent 1B</p>
        </def>
      </def-item>
      <def-item>
        <term>GRP</term>
        <def>
          <p>gastrin&#8208;releasing peptide</p>
        </def>
      </def-item>
      <def-item>
        <term>INSM1</term>
        <def>
          <p>insulinoma&#8208;associated protein 1</p>
        </def>
      </def-item>
      <def-item>
        <term>LSD1/KDM1A</term>
        <def>
          <p>lysine&#8208;specific histone demethylase 1A</p>
        </def>
      </def-item>
      <def-item>
        <term>MLL1/2</term>
        <def>
          <p>mixed lineage leukemia protein 1/2</p>
        </def>
      </def-item>
      <def-item>
        <term>NEUROD1</term>
        <def>
          <p>neurogenic differentiation 1</p>
        </def>
      </def-item>
      <def-item>
        <term>PDX</term>
        <def>
          <p>patient&#8208;derived xenografts</p>
        </def>
      </def-item>
      <def-item>
        <term>RB1</term>
        <def>
          <p>retinoblastoma protein 1</p>
        </def>
      </def-item>
      <def-item>
        <term>scRNA&#8208;seq</term>
        <def>
          <p>single cell RNA sequencing</p>
        </def>
      </def-item>
      <def-item>
        <term>SNAG</term>
        <def>
          <p>SNAIL/Gfi&#8208;1 family zinc finger proteins</p>
        </def>
      </def-item>
      <def-item>
        <term>TEAD4</term>
        <def>
          <p>TEA domain family member 4</p>
        </def>
      </def-item>
      <def-item>
        <term>VIM</term>
        <def>
          <p>vimentin</p>
        </def>
      </def-item>
      <def-item>
        <term>ZEB1</term>
        <def>
          <p>zinc finger E&#8208;box&#8208;binding homeobox 1</p>
        </def>
      </def-item>
    </def-list>
    <sec id="mol213124-sec-0001">
      <label>1</label>
      <title>Introduction</title>
      <p>Small&#8208;cell lung cancer (SCLC) is a neuroendocrine carcinoma that exhibits aggressive malignancy and a high propensity for early metastasis. In addition to common mutations in RB1 and TP53, molecular profiling studies have identified an epigenetic basis for SCLC disease initiation and progression featuring frequent mutations in chromatin&#8208;modifying genes including CREBBP, EP300, and MLL1/2 as well as alterations in the distribution of DNA methylation [<xref rid="mol213124-bib-0001" ref-type="bibr">1</xref>]. Based on these observations, epigenetic drugs have been explored for therapeutic intervention to target tumor&#8208;specific epigenetic vulnerabilities and reverse acquired epigenetic changes driving tumor growth and survival. Promising <italic toggle="yes">in&#8201;vitro</italic> and <italic toggle="yes">in&#8201;vivo</italic> preclinical data led to clinical trials exploring the use of histone deacetylase inhibitors including romidepsin or panobinostat in relapsed SCLC. Although both agents were well&#8208;tolerated and demonstrated some evidence of tumor shrinkage and sustained stable disease, both clinical studies failed to demonstrate a significant benefit warranting continued development [<xref rid="mol213124-bib-0002" ref-type="bibr">2</xref>].</p>
      <p>The emergence of a new generation of epigenetic drugs targeting specific transcriptional regulators of SCLC oncogenesis including BRD4, LSD1, and EZH2 has renewed interest in exploring epigenetic therapies in SCLC [<xref rid="mol213124-bib-0003" ref-type="bibr">3</xref>, <xref rid="mol213124-bib-0004" ref-type="bibr">4</xref>, <xref rid="mol213124-bib-0005" ref-type="bibr">5</xref>]. Among this class of new epigenetic drugs, inhibitors of the histone lysine demethylase LSD1 (KDM1A) have gained significant attention [<xref rid="mol213124-bib-0006" ref-type="bibr">6</xref>]. LSD1 is a member of the BRAF&#8208;HDAC (BHC) corepressor complex shown to regulate expression of neuronal gene programs through interaction with REST [<xref rid="mol213124-bib-0007" ref-type="bibr">7</xref>, <xref rid="mol213124-bib-0008" ref-type="bibr">8</xref>, <xref rid="mol213124-bib-0009" ref-type="bibr">9</xref>, <xref rid="mol213124-bib-0010" ref-type="bibr">10</xref>, <xref rid="mol213124-bib-0011" ref-type="bibr">11</xref>, <xref rid="mol213124-bib-0012" ref-type="bibr">12</xref>]. In addition to the previously reported antitumor activity in acute myeloid leukemia, LSD1 inhibitors have shown lineage&#8208;specific activity in SCLC cell lines and patient&#8208;derived xenograft models [<xref rid="mol213124-bib-0005" ref-type="bibr">5</xref>, <xref rid="mol213124-bib-0006" ref-type="bibr">6</xref>, <xref rid="mol213124-bib-0013" ref-type="bibr">13</xref>, <xref rid="mol213124-bib-0014" ref-type="bibr">14</xref>, <xref rid="mol213124-bib-0015" ref-type="bibr">15</xref>]. Although the mechanism of growth arrest conferred by these drugs is unclear, LSD1 has been shown to regulate neuroendocrine transcriptional programs critical for SCLC growth [<xref rid="mol213124-bib-0005" ref-type="bibr">5</xref>, <xref rid="mol213124-bib-0013" ref-type="bibr">13</xref>]. Several recent reports have suggested that the primary mechanism of action of LSD1 inhibitors in both AML and SCLC occurs not only through catalytic inhibition of LSD1 enzymatic function but also through inhibition of the interaction of LSD1 with SNAG domain transcriptional factors such as INSM and GFI1B [<xref rid="mol213124-bib-0014" ref-type="bibr">14</xref>, <xref rid="mol213124-bib-0015" ref-type="bibr">15</xref>]. Through these inhibitory mechanisms, LSD1 inhibitors can impact the expression of neuroendocrine lineage&#8208;specific regulators such as ASCL1, required for SCLC lineage specification.</p>
      <p>Recent studies have characterized SCLC as heterogeneous population, consisting of intratumoral and intertumoral neuroendocrine (ASCL1/NEUROD1), mesenchymal&#8208;like, and YAP&#8208;driven transcriptional states and subtypes [<xref rid="mol213124-bib-0016" ref-type="bibr">16</xref>, <xref rid="mol213124-bib-0017" ref-type="bibr">17</xref>]. The particular SCLC subtypes may define vulnerabilities to therapeutic targets. In a breadth of efficacy screen, Mohammad <italic toggle="yes">et&#8201;al</italic>. [<xref rid="mol213124-bib-0005" ref-type="bibr">5</xref>] identified only a subset of SCLC cell lines and primary samples with a DNA hypomethylation signature undergoing growth inhibition in response to GSK2879552. Similarly, in a panel of SCLC PDX tumors, Augert <italic toggle="yes">et&#8201;al</italic>. [<xref rid="mol213124-bib-0013" ref-type="bibr">13</xref>] identified selective activity of ORY&#8208;1001 only in models capable of NOTCH pathway activation. Moreover, many sensitive SCLC cell lines and primary tumor models display only partial responses to LSD1 inhibition even after long durations of treatment. The recent advancement of both irreversible and reversible LSD1 inhibitors into SCLC clinical trials warrants the study of potential drug resistance mechanisms that may prevent patients from responding to this class of drugs.</p>
      <p>In this study, we have addressed potential intrinsic and acquired drug resistance mechanisms to LSD1 inhibitors in SCLC. Utilizing a recently identified gene coexpression network defining SCLC neuroendocrine and mesenchymal states [<xref rid="mol213124-bib-0018" ref-type="bibr">18</xref>, <xref rid="mol213124-bib-0019" ref-type="bibr">19</xref>], we have identified that sensitivity to LSD1 inhibitors in SCLC is confined primarily to cell lines that express neuroendocrine transcriptional programs. Heterogeneous drug responses in SCLC cell lines reflect a preexisting cell intrinsic drug resistance mechanism enriched in cell lines expressing mesenchymal&#8208;like transcriptional programs. Using single cell RNA&#8208;seq and ATAC&#8208;seq, we demonstrate that continuous treatment with LSD1 inhibitors results in the emergence of drug&#8208;tolerant subclones with a <italic toggle="yes">de&#8201;novo</italic> mesenchymal&#8208;like transcriptional state driven through a TEAD4 transcription factor program. We also highlight that acquired resistance to LSD1 inhibitors appears as an &#8216;epi&#8208;stable&#8217; state. Under drug withdrawal, drug&#8208;tolerant SCLC cells transition between mesenchymal and neuroendocrine phenotypes and regain sensitivity to the drug. Collectively our data provide novel insight in the mechanism contributing to heterogeneous responsiveness of SCLC to LSD1 inhibitors, and selection of mesenchymal&#8208;like enriched subclones is likely to present a barrier to effective single&#8208;agent responses in the clinic.</p>
    </sec>
    <sec sec-type="materials-and-methods" id="mol213124-sec-0002">
      <label>2</label>
      <title>Materials and methods</title>
      <sec id="mol213124-sec-0003">
        <label>2.1</label>
        <title>Cell lines and reagents</title>
        <p>Human SCLC cell lines used in this study were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) , Sigma&#8208;Aldrich (St. Louis, MO, USA), or Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ, Brunswick, Germany) and grown in manufacturer&#8217;s specified growth medium and environmental conditions. Cell growth medium was purchased from Life Technologies (Carlsbad, CA, USA) or Lonza (Basel, Switzerland).</p>
        <p>GSK690 [<xref rid="mol213124-bib-0020" ref-type="bibr">20</xref>] and OG&#8208;86 [<xref rid="mol213124-bib-0021" ref-type="bibr">21</xref>] were synthesized by WuXi AppTec (Shanghai, China) using previously disclosed structures. Structures were confirmed using NMR (nuclear magnetic resonance spectroscopy) and LCMS (liquid chromatography&#8211;mass spectrometry). Compounds were solvated in DMSO (Sigma, St. Louis, MO, USA) at 30&#8201;m<sc>m</sc> for use in <italic toggle="yes">in&#8201;vitro</italic> experiments.</p>
      </sec>
      <sec id="mol213124-sec-0004">
        <label>2.2</label>
        <title>Human lung cancer tissue microarray</title>
        <p>Lung cancer tumor microarray (14&#8211;140) was purchased from US Biomax, Inc. (Derwood, MD, USA) Immunohistochemical staining and evaluation were performed on a single TMA slide containing 200 microarray dot tissue samples representing a broad array of human lung cancer histologic subtypes as well the inclusion of 20 normal lung tissue samples for comparison. Immunohistochemical procedure and staining were developed and optimized with known LSD1&#8208;positive control tissues to ensure proper specificity. Pathologist scoring method for all evaluated TMA cores was semiquantitative and based on a range of tumor cell positivity corresponding to each score, with a score of 1 indicating rare positivity, 2 showing 3&#8211;10% positivity, 3 showing 11&#8211;30% positivity, and 4 for everything greater than 30.</p>
        <p>Immunohistochemical&#8208;stained slides were prepared using a Leica Bond automated staining system. Briefly, slides underwent antigen retrieval (Leica ER2, Wetzlar, Germany) for 20&#8201;min followed by incubation with rabbit anti&#8208;LSD1 1&#8201;:&#8201;100 (Cell Signaling Technology, Danvers, MA, USA, #2139) for 40&#8201;min at room temperature. Bond Polymer Refine (Buffalo Grove, IL, USA, Bond #DS9800) kit with poly&#8208;HRP and 3,3&#8208;diaminobenzidine tetrahydrochloride (DAB substrate chromogen) was used to detect and visualize the LSD1 staining. Finally, the slides were counterstained with hematoxylin, dehydrated, and mounted. The study methodologies conformed to the standards set by the Declaration of Helsinki and were approved by Pfizer ethics committee.</p>
      </sec>
      <sec id="mol213124-sec-0005">
        <label>2.3</label>
        <title>Preparation of cell extracts and western blot analysis</title>
        <p>Adherent and suspension cell populations were collected and washed in PBS prior to lysis in RIPA buffer (Sigma) with protease inhibitor cocktails (Roche, South San Francisco, CA, USA) plus PMSF. Cell lysates were briefly sonicated prior and precleared by centrifugation. 30&#8201;&#181;g of protein was loaded on 4&#8211;12% SDS/PAGE and transferred to nitrocellulose membranes. Samples were incubated overnight at 4&#8201;&#176;C in primary antibodies and 1&#8201;h at room temperature in secondary antibodies. Imaging was performed using LiCor Imaging System (Lincoln, NE, USA).</p>
        <p>Antibodies used in this study are KDM1A (Millipore cs207350, Bethyl, Montgomery, TX, USA, A300&#8208;215A), NSE (CST, Danvers, MA, USA, 9536), SYP (CST 12270), GRP (Sigma HPA007314), NCAM (CST 3576), CHGA (Abcam, Branford, CT, USA, 45179), FOXA2 (CST 3143), OVOL2 (Abcam 129161), LEF1 (CST 2286), ASCL1 (Abnova, Walnut, CA, USA, H0429&#8208;M02), SOX2 (CST 4900), INSM1 (Abcam 170876), NEUROD1 (117562), SMAD3 (CST 9513), NFKB2 (CST 3017), CMYC (CST 9402), MITF (Abcam 140606), SNAIL (CST 3895), VIM (CST 5741), CDH2 (CST 14215), CDH1 (CST 3195P), and ZEB1 (CST 3396P).</p>
      </sec>
      <sec id="mol213124-sec-0006">
        <label>2.4</label>
        <title>Long&#8208;term cell proliferation assays</title>
        <p>For drug sensitivity studies, cell lines were plated in triplicate 10&#8208;cm<sup>2</sup> dishes at drug concentrations of 1000, 300, 100, 30, 10, 3, and 1&#8201;n<sc>m</sc> in DMSO. Every 3 or 4&#8201;days, adherent and suspension cells were collected and 2&#8201;mL of cells was transferred to a new 10&#8208;cm<sup>2</sup> dishes for subsequent culture. 8&#8201;mL of fresh cell culture medium was added to each plate, and drug was added at proper concentrations to each dish. Three aliquots of 1&#8201;mL of cells were collected in 1.5&#8208;mL microcentrifuge tube, concentrated by centrifugation to a 100&#8201;&#181;L volume, and added to a 96&#8208;well plate. Relative cell numbers were determined either by cell counting of three independent aliquots using a hemocytometer or by CellTiter&#8208;Glo reagent (Promega, Madison, WI, USA).</p>
      </sec>
      <sec id="mol213124-sec-0007">
        <label>2.5</label>
        <title>RNA&#8208;seq and expression profiling experiments</title>
        <p>RNA&#8208;seq was accomplished on SCLC cell lines treated in triplicate with DMSO or 0.3&#8201;&#181;<sc>m</sc> GSK690 for either 3 or 10&#8201;days. RNA&#8208;seq libraries were generated following manufacture&#8217;s protocols and sequenced paired&#8208;end on the HiSeq 2000 at read length 50 or 100&#8201;nt (only for COR&#8208;L88). FastQ data generated by HiSeq were QCed and trimmed before being aligned to the HG19 human reference genome and then quantified using the <sc>rsem</sc> package [<xref rid="mol213124-bib-0022" ref-type="bibr">22</xref>] The RNA&#8208;seq DE (differential expression) analysis was done by using the <sc>deseq r</sc> package after <sc>rsem</sc> [<xref rid="mol213124-bib-0023" ref-type="bibr">23</xref>]. For this analysis, the program used raw counts as input and ran its normalization method using a scaling factor computed as the median of the ratio, for each gene, of its read count over its geometric mean across all lanes.</p>
        <p>The SCLC cell line mRNA expression data were downloaded from CCLE 19Q1 [<xref rid="mol213124-bib-0024" ref-type="bibr">24</xref>]. For differential expression analysis, genes that are not expressed (TPM &lt;&#8201;3 in all cell lines) are first removed, and moderated <italic toggle="yes">t</italic>&#8208;test was conducted using <sc>limma</sc> package with Empirical Bayes shrinkage [<xref rid="mol213124-bib-0025" ref-type="bibr">25</xref>] in sensitive (<italic toggle="yes">n</italic>&#8201;=&#8201;10) vs resistant (<italic toggle="yes">n</italic>&#8201;=&#8201;12) cell lines using log2&#8208;TPM values with FDR multiple testing correction. Differential expression cutoff is set at FDR &lt;&#8201;5% and FC &gt;&#8201;2. The heatmaps were generated using the <sc>complex heatmap</sc> package in <sc>r</sc> [<xref rid="mol213124-bib-0026" ref-type="bibr">26</xref>]. To identify enriched pathways associated with LSD1 sensitivity, we calculated a significance score defined as follows: &#8722;log2(FDR) X (difference in mean TPM between sensitive and resistant lines) and loaded this score into GSEA prerank for pathway analysis [<xref rid="mol213124-bib-0027" ref-type="bibr">27</xref>]. The neuroendocrine (NE) and mesenchymal&#8208;like (ML) network signature genes for 53 SCLC CCLE cell lines were defined as previously described [<xref rid="mol213124-bib-0019" ref-type="bibr">19</xref>, <xref rid="mol213124-bib-0028" ref-type="bibr">28</xref>]. For overlapping analysis between differential genes and NE/ML network genes, hypergeometric test was performed between each gene set, and the median TPM value of NE or ML module genes was plotted with boxplot with two&#8208;sample <italic toggle="yes">t</italic>&#8208;test on sensitive and resistant cell lines.</p>
        <p>For TCGA SCLC tumor gene expression analysis, the 2015 UCologne RNA&#8208;seq <italic toggle="yes">z</italic>&#8208;score data were downloaded from cBio portal (<ext-link ns1:href="https://www.cbioportal.org/" ext-link-type="uri">https://www.cbioportal.org/</ext-link>). Genes containing NA readings were removed, and duplicated gene names were merged by their mean expression <italic toggle="yes">z</italic>&#8208;score. This resulted in a total of 18&#8201;598 genes in 81 patient tumors. To calculate gene signature scores, the median expression <italic toggle="yes">z</italic>&#8208;score from each signature was calculated for each tumor. The gene expression heatmap was generated using the <sc>complex heatmap</sc> package in <sc>r</sc> [<xref rid="mol213124-bib-0026" ref-type="bibr">26</xref>].</p>
      </sec>
      <sec id="mol213124-sec-0008">
        <label>2.6</label>
        <title>Single cell isolation and scRNA&#8208;seq</title>
        <p>NCI&#8208;H69 cells were treated in duplicate with DMSO or 0.3&#8201;&#956;<sc>m</sc> GSK690 for 21&#8201;days. The single cell suspension was isolated by passing the harvested cells through a 40&#8208;&#956;m Flowmi<sup>TM</sup> tip strainer followed by incubation with 0.25% Trypsin&#8208;EDTA in ice for 10&#8201;min and at 37&#8201;&#176;C for 10&#8201;min to get a final concentration of 3&#8201;&#215;&#8201;10<sup>5</sup>&#8201;cells&#183;mL<sup>&#8722;1</sup>. The single cells were then processed through the Chromium 3&#8242; Single Cell Platform using v2 reagents (10X Genomics, Pleasanton, CA, USA) per the manufacturer&#8217;s protocol. In brief, a total of 6536 single cells were detected with 3603 cells analyzed in the DMSO vehicle group and 2903 in LSD1 inhibitor&#8208;treated group. The cells were partitioned into Gel Beads in Emulsion in the Chromium instrument, where cell lysis and barcoded reverse transcription of RNA occurred, followed by amplification, shearing, and 5&#8242; adaptor and sample index attachment. Libraries were sequenced on an Illumina HiSeq 4000 (San Diego, CA, USA).</p>
        <p>For single cell RNA&#8208;seq analysis, gene&#8208;cell count matrix was generated with Cellranger pipeline (10X Genomics, Pleasanton, CA, USA). All downstream analyses, including cell filtering, data normalization, and cell clustering, were performed using the <sc>r seurat v3</sc> package [<xref rid="mol213124-bib-0029" ref-type="bibr">29</xref>]. In brief, to remove low&#8208;quality data, cells that have unique gene counts between 200 and 6000 and mitochondrial reads &lt;&#8201;10% were kept for further analysis. Read counts were then normalized for total counts in each cell, scaled to 10&#8201;000, and then log&#8208;transformed. To remove confounding factors associated with assay quality and cell cycle stages, we used SCTransform [<xref rid="mol213124-bib-0030" ref-type="bibr">30</xref>] to regress out percent mitochondrial reads, percent ribosomal reads, and cell cycle S/G2M score in each single cell. Top 3000 variable genes were selected for downstream analysis. To facilitate single cell comparison between control and LSD1 inhibitor treatment, we used Harmony package [<xref rid="mol213124-bib-0031" ref-type="bibr">31</xref>] with default settings to integrate single cell data and used UMAP [<xref rid="mol213124-bib-0032" ref-type="bibr">32</xref>] for two&#8208;dimensional data embedding. Differentially expressed genes between each cluster or control vs drug&#8208;treated cells were called using the Seurat &#8216;FindMarkers&#8217; function with these parameters: min.pct&#8201;=&#8201;0.2, logfc. threshold&#8201;=&#8201;0.25, with a cutoff of FDR &lt;&#8201;5%. Gene expression values or scores in UMAP were capped at 5% and 95% quantile to eliminate outlier bias during data representation.</p>
      </sec>
      <sec id="mol213124-sec-0009">
        <label>2.7</label>
        <title>ATAC&#8208;seq and data analysis</title>
        <p>NCI&#8208;H69 cells were treated in triplicate with DMSO or 0.3&#8201;&#956;<sc>m</sc> GSK690 for 21&#8201;days. The transposition assay was performed. Briefly, 50&#8201;000 nuclei from each sample were used in each reaction with 20&#8201;&#181;L of transposition mix and incubated at 37&#8201;&#176;C for 60&#8201;min. qPCR was performed, and eight cycles were performed. The library was purified with Ampure XP beads (A63880, Beckman Coulter, Brea, CA, USA), quantified using Qubit (Qubit dsDNA HS Assay Kit, Q32851, Thermo Fisher Scientific, San Diego, CA, USA), and checked for size distribution using 4200 TapeStation (High Sensitivity D1000 ScreenTape, 5067&#8208;5584, Agilent Technologies, Santa Clara, CA, USA). Sequencing was performed with Illumina HiSeq4000 (San Diego, CA, USA) (50&#8201;bp PE, Nextera v2 libraries).</p>
        <p>For ATAC&#8208;seq data analysis, paired&#8208;end sequencing reads for each sample were mapped to hg38 human reference genome with Bowtie 2 [<xref rid="mol213124-bib-0033" ref-type="bibr">33</xref>] using the following parameters: &#8208;t &#8208;X 2000 &#8208;&#8208;no&#8208;mixed &#8208;&#8208;no&#8208;discordant. Sam files were converted into Bam with <sc>samtools</sc>. Peak calling was performed with MACS2 [<xref rid="mol213124-bib-0034" ref-type="bibr">34</xref>] using these parameters: callpeak &#8208;g hs &#8208;&#8208;nolambda &#8208;&#8208;nomodel &#8208;&#8208;shift &#8208;100 &#8208;&#8208;extsize 200 &#8208;&#8208;bdg &#8208;&#8208;SPMR &#8208;q 5e&#8208;2. Peaks overlap with ENCODE black list regions were removed from downstream analysis using <sc>bedtools</sc>. BedGraph files were converted to Bigwig using <sc>bedgraphtobigwig</sc> [<xref rid="mol213124-bib-0035" ref-type="bibr">35</xref>], and signal tracks were visualized with IGV [<xref rid="mol213124-bib-0036" ref-type="bibr">36</xref>]. To correct for ATAC&#8208;seq bias, we extracted genome&#8208;wide signal at 100&#8208;bp resolution using <sc>deeptools</sc> [<xref rid="mol213124-bib-0037" ref-type="bibr">37</xref>] and performed quantile normalization on the signal data using the <sc>r</sc> package <sc>preprocesscore</sc> (<ext-link ns1:href="https://rdrr.io/bioc/preprocessCore/" ext-link-type="uri">https://rdrr.io/bioc/preprocessCore/</ext-link>). Differential peak calling between the control and drug&#8208;treated samples was performed with DESeq2 [<xref rid="mol213124-bib-0038" ref-type="bibr">38</xref>], using merged peaks between all samples (total 250&#8201;646 peaks). Significant differential peaks were defined as follows: FDR &lt;&#8201;0.01 &amp; fold change &gt;&#8201;2.5, and the mean read count for each peak is &gt;&#8201;40% quantile of all mean read count (to remove low signal regions). This results in 548 open peaks and 838 closed peaks after drug treatment. GREAT analysis [<xref rid="mol213124-bib-0039" ref-type="bibr">39</xref>] was performed on the differential peaks to identify pathways associated with the drug treatment. To predict transcription factor (TF) binding perturbed by the drug treatment, we employed <sc>chromvar</sc> package [<xref rid="mol213124-bib-0040" ref-type="bibr">40</xref>] with the &#8216;human_pwms_v2 motif&#8217; database to identify TF binding DNA motifs that are significantly open or closed upon treatment. <italic toggle="yes">t</italic>&#8208;Test with FDR correction was performed on all TF <italic toggle="yes">z</italic>&#8208;scores to identify significant TF motifs.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="mol213124-sec-0010">
      <label>3</label>
      <title>Results</title>
      <sec id="mol213124-sec-0011">
        <label>3.1</label>
        <title>LSD1 is highly expressed in small&#8208;cell lung cancer relative to other lung cancer subtypes</title>
        <p>Overexpression of chromatin modifiers has been shown to influence their function in cancer [<xref rid="mol213124-bib-0041" ref-type="bibr">41</xref>]. In lung cancer, LSD1 mRNA expression is highly expressed in SCLC relative to other lung cancer cell lines (Fig.&#8201;<xref rid="mol213124-fig-0001" ref-type="fig">1A</xref>). Expression datasets from Clinical Lung Cancer Genome Project (CLCGP) [<xref rid="mol213124-bib-0042" ref-type="bibr">42</xref>] confirm LSD1 is also expressed highly relative to other lung cancer subtypes in primary patient samples (Fig.&#8201;<xref rid="mol213124-fig-0001" ref-type="fig">1B</xref>). To further confirm LSD1 expression levels at the protein level, we conducted immunohistochemistry (IHC) on a lung cancer tissue microarray. IHC staining confirmed a statistically significantly higher staining intensity in SCLC specimens relative to that of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma (1&#8208;way ANOVA Fig.&#8201;<xref rid="mol213124-fig-0001" ref-type="fig">1C,D</xref>).</p>
        <fig position="float" fig-type="Fig." id="mol213124-fig-0001">
          <label>Fig. 1</label>
          <caption>
            <p>LSD1 is highly expressed in small&#8208;cell lung cancer relative to other lung cancer subtypes. (A) Expression of LSD1 (KDM1A) mRNA from <italic toggle="yes">n</italic>&#8201;=&#8201;185 lung cancer cell lines derived from the CCLE dataset at the Broad Institute. (B) LSD1 expression data in 261 primary lung tumors from Clinical Lung Cancer Genome Project (CLCGP). (C) Representative images of LSD1 expression with scale bar at 250&#8201;&#181;m by immunohistochemistry (IHC) in <italic toggle="yes">n</italic>&#8201;=&#8201;200 lung cancer tissue microarray. (D) Quantitation of LSD1 expression in <italic toggle="yes">n</italic>&#8201;=&#8201;200 microarray dot tissue samples all from a broad array of human lung cancer histologic subtypes and including <italic toggle="yes">n</italic>&#8201;=&#8201;20 normal lung samples for comparison. LSD1 IHC immunoreactivity was given a histologic semiquantitative score (0&#8211;4; 4 being highest intensity staining) for each sample. Data presented represent mean &#177;&#8201;1 standard deviation (SD). Statistical significance was determined by one&#8208;way ANOVA with Tukey HSD <italic toggle="yes">post&#8201;hoc</italic> test for (A), (B), and (D).</p>
          </caption>
          <graphic ns1:href="MOL2-16-1309-g001" position="anchor" id="jats-graphic-3" />
        </fig>
      </sec>
      <sec id="mol213124-sec-0012">
        <label>3.2</label>
        <title>SCLC cell lines show heterogeneous responses to LSD1 inhibitors</title>
        <p>Resulting from the observation of high expression of LSD1 in SCLC, we assessed whether SCLC cell lines were dependent on LSD1 activity for their growth. Using two shRNAs targeting LSD1, we observed growth inhibition in the NCI&#8208;H526 cell line that became strongest after 14&#8201;days of target knockdown (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S1</xref>A). Interestingly, DMS&#8208;114 cells did not appear sensitive to LSD1 knockdown over 14&#8201;days even though there was a significant loss of LSD1 protein level by western blot (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S1</xref>B).</p>
        <p>Several reports have recently described sensitivity in SCLC cell lines to LSD1 inhibitors. To study this further, we profiled drug sensitivity to the FAD reversible inhibitor GSK690 (Ki&#8201;=&#8201;4&#8201;n<sc>m</sc>) [<xref rid="mol213124-bib-0020" ref-type="bibr">20</xref>] as well as the FAD irreversible compound OG&#8208;86 (IC50&#8201;=&#8201;47&#8201;n<sc>m</sc>) [<xref rid="mol213124-bib-0021" ref-type="bibr">21</xref>] in a panel of SCLC cell lines (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S2</xref>). Due to the delayed onset of proliferation changes observed in shRNA experiments, we tested the effects of GSK690 and OG&#8208;86 on SCLC cell line growth in long&#8208;term proliferation assays of 17&#8211;21&#8201;days. Consistent with shRNA results, we observed differential responses in many SCLC cell lines. In NCI&#8208;H1417, NCI&#8208;H187, and NCI&#8208;H889 cells, dose&#8208;dependent growth inhibition was initially observed at 7&#8211;10&#8201;days of both GSK690 and OG&#8208;86 treatments with continued effects observed until days 17&#8211;21 (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S3</xref>A&#8211;C). DMS&#8208;114 cells, which were insensitive to LSD1 shRNA knockdown, were also insensitive to both GSK690 and OG&#8208;86 up to 17&#8201;days of treatment at concentrations up to 1.0&#8201;&#181;<sc>m</sc> OG&#8208;86 and 1.0&#8201;&#181;<sc>m</sc> GSK690 (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S3</xref>D). Treatment with LSD1 inhibitors resulted in cytostatic responses in sensitive SCLC cell lines. In COR&#8208;L88 and NCI&#8208;H1417 cells, an increase in sub&#8208;G1 phase was observed upon 7&#8201;days of GSK690 treatment (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S3</xref>E) along with an increase in cells in G1 phase (42% G1 for 1&#8201;&#181;<sc>m</sc> GSK690 vs 25% G1 for DMSO in COR&#8208;L88 cells; Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S3</xref>F). In contrast, GSK690 treatment in NCI&#8208;H526 arrested cell growth without obvious accumulation in any stage of the cell cycle (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S3</xref>E). Interestingly, the antiproliferative effects of LSD1 inhibitors plateau in their percent inhibition even after 17&#8211;21&#8201;days of continuous drug treatment due to the emergence of a subpopulation of slowly proliferative persister cells in NCI&#8208;H1417 and NCI&#8208;H187 cells (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S3</xref>). These data suggest that SCLC cell lines possess both intrinsic and acquired resistance mechanisms to LSD1 inhibitors.</p>
      </sec>
      <sec id="mol213124-sec-0013">
        <label>3.3</label>
        <title>Neuroendocrine and mesenchymal expression signatures stratify sensitivity to LSD1 inhibition</title>
        <p>Across the SCLC cell line panel, 12 out of 29 tested SCLC cell lines showed &gt;&#8201;50% growth inhibition in response to 0.3&#8201;&#181;<sc>m</sc> GSK690 treatment at day 17 (Fig.&#8201;<xref rid="mol213124-fig-0002" ref-type="fig">2A</xref>). A nonenzymatic mechanism of action has recently been proposed to account for the antitumor activity of LSD1 inhibitors in SCLC [<xref rid="mol213124-bib-0015" ref-type="bibr">15</xref>]. In our cell panel, we identified that all SCLC cell lines sensitive to GSK690 express SNAG domain proteins INSM1 or GFI1B; however, we also observed examples of INSM1 or GFI1B&#8208;expressing cell lines that were also resistant to the drug (Fig.&#8201;<xref rid="mol213124-fig-0002" ref-type="fig">2C</xref>). Thus, the expression of SNAG domain proteins alone is insufficient to define cell lines that will respond to GSK690.</p>
        <fig position="float" fig-type="Fig." id="mol213124-fig-0002">
          <label>Fig. 2</label>
          <caption>
            <p>Differential sensitivity of SCLC cell lines to LSD1 inhibitors stratifies with expression of neuroendocrine markers. (A) SCLC cell sensitivity to 0.3&#8201;&#181;<sc>m</sc> GSK690 at day 17 based on the percentage of remaining cells relative to DMSO control. Long&#8208;term proliferation assays were run with <italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent replicates presented with mean&#8201;&#177;&#8201;SD. Sensitive cell lines are reflected by &gt;&#8201;50% growth inhibition, resistant cell lines at &lt;&#8201;20% growth inhibition. (B) Expression of LSD1, GRP, ASCL1, VIM, and ZEB1 in GSK690&#8208;sensitive and GSK690&#8208;resistant cell lines based on CCLE mRNA expression data, <italic toggle="yes">n</italic>&#8201;=&#8201;2 independent experiments performed &#177;&#8201;SD. Two sample <italic toggle="yes">t</italic>&#8208;test **<italic toggle="yes">P</italic>&#8208;values &lt;&#8201;0.05 are shown. (C) Heatmap of CCLE mRNA expression of specific marker genes defining SCLC subtypes. Gene expression values are shown as row normalized <italic toggle="yes">z</italic>&#8208;scores from log2(TPM+1). (D) GSK690 dose response in NCI&#8208;H69 compared with NCI&#8208;H69V cells at day 17 in the mean of <italic toggle="yes">n</italic>&#8201;=&#8201;2 independent experiments performed in quadruplets &#177;&#8201;SD. Two&#8208;way ANOVA multiple comparisons with *<italic toggle="yes">P</italic>&#8208;values &lt;&#8201;0.001 are shown. Western blot using indicated antibodies demonstrating protein expression of neuroendocrine (NE) and mesenchymal (ML) markers in NCI&#8208;H69 and NCI&#8208;H69V cells.</p>
          </caption>
          <graphic ns1:href="MOL2-16-1309-g005" position="anchor" id="jats-graphic-5" />
        </fig>
        <p>To identify additional biomarkers that predict sensitivity to GSK690, we explored both mutational and gene expression features of SCLC cell lines from available CCLE data [<xref rid="mol213124-bib-0024" ref-type="bibr">24</xref>] LSD1 expression level alone did not correlate with drug sensitivity (Fig.&#8201;<xref rid="mol213124-fig-0002" ref-type="fig">2B,C</xref>). Additionally, using both univariate and multivariate association methods, no mutation significantly correlated with cell line sensitivity (data not shown). Analysis of the cell line gene expression by principal component analysis suggests that cell lines sensitive to GSK690 stratify in a group with distinct transcriptional state compared to insensitive cell lines with exception of NCI&#8208;H526 and NCI&#8208;H1963 cells that appear to be outliers (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S4</xref>A). SCLC cell lines can be stratified by neuroendocrine/epithelial (NE) and mesenchymal&#8208;like (ML) features. Using established gene expression markers of these SCLC cell states [<xref rid="mol213124-bib-0016" ref-type="bibr">16</xref>, <xref rid="mol213124-bib-0017" ref-type="bibr">17</xref>], we found enrichment in GSK690&#8208;sensitive cell lines in expression of epithelial genes, MYCL and EPCAM, and neuroendocrine genes, GRP, DDC, and ASCL1 (Fig.&#8201;<xref rid="mol213124-fig-0002" ref-type="fig">2B,C</xref> and Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S5</xref>). SCLC cell lines resistant to GSK690 featured higher expression of mesenchymal genes MYC, ZEB1, and VIM (Fig.&#8201;<xref rid="mol213124-fig-0002" ref-type="fig">2B,C</xref> and Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S5</xref>). These data suggest that neuroendocrine&#8208;like SCLC cell lines may be more sensitive to LSD1 inhibition while mesenchymal&#8208;like SCLC states may confer resistance to LSD1 inhibitors.</p>
        <p>To experimentally address the intrinsic drug resistance of mesenchymal&#8208;shifted SCLC cells to LSD1 inhibitors, we treated a mesenchymal variant form of NCI&#8208;H69 cells, NCI&#8208;H69V [<xref rid="mol213124-bib-0043" ref-type="bibr">43</xref>] with GSK690. NCI&#8208;H69 cells grow in suspension and show enrichment in NE transcription factors FOXA2, SOX2, LEF1, NCAM, and E&#8208;cadherin (Fig.&#8201;<xref rid="mol213124-fig-0002" ref-type="fig">2D</xref>). In contrast, NCI&#8208;H69V cells grow as adherent cells and express a ML signature&#8208;enriched transcription factors SMAD3, MYC, ZEB1, and VIM [<xref rid="mol213124-bib-0019" ref-type="bibr">19</xref>] (Fig.&#8201;<xref rid="mol213124-fig-0002" ref-type="fig">2D</xref>). In line with our hypothesis, mesenchymal&#8208;shifted NCI&#8208;H69V appeared to be resistant to GSK690 treatment, showing only 22% growth inhibition compared with 85% growth inhibition observed in parental NCI&#8208;H69 cells (Fig.&#8201;<xref rid="mol213124-fig-0002" ref-type="fig">2D</xref>).</p>
        <p>To further refine the gene expression signature associated with LSD1 inhibitor resistance, we performed differential expression analysis between LSD1 inhibition sensitive and resistant SCLC cells from CCLE cell line data. Using this approach, we identified a differential gene expression signature (FDR &lt;&#8201;5% and FC &gt;&#8201;2) stratifying cell lines sensitive and resistant to LSD1 inhibitors (Fig.&#8201;<xref rid="mol213124-fig-0003" ref-type="fig">3A</xref>). By performing Gene Set Enrichment Analysis (GSEA) [<xref rid="mol213124-bib-0027" ref-type="bibr">27</xref>] on these differential genes, we found that gene sets of ASCL1 targets, epithelial differentiation, and ZEB1 repressive sites are upregulated in the sensitive cells, whereas EMT, TGF&#8208;beta, and MYC pathway gene sets are significantly upregulated in the resistant cells (Fig.&#8201;<xref rid="mol213124-fig-0003" ref-type="fig">3B</xref>).</p>
        <fig position="float" fig-type="Fig." id="mol213124-fig-0003">
          <label>Fig. 3</label>
          <caption>
            <p>Connection of LSD1 sensitivity signature with neuroendocrine and mesenchymal&#8208;like network signatures. (A) CCLE gene expression heatmap with hierarchical clustering of differentially expressed (DE) genes between sensitive (<italic toggle="yes">n</italic>&#8201;=&#8201;10) and resistant (<italic toggle="yes">n</italic>&#8201;=&#8201;12) cell lines. Gene expression values are shown as row <italic toggle="yes">z</italic>&#8208;score. DE gene cutoff is FDR &lt;&#8201;5% and FC &gt;&#8201;2. (B) Gene Set Enrichment Analysis (GSEA) of differential gene expression between sensitive and resistant cell lines from (A). (C) Boxplot depicting the CCLE median expression values (TPM) of previously published neuroendocrine (NE) and mesenchymal&#8208;like (ML) signatures [<xref rid="mol213124-bib-0019" ref-type="bibr">19</xref>] in sensitive and resistant cell lines from (A). Two sample <italic toggle="yes">t</italic>&#8208;test <italic toggle="yes">P</italic>&#8208;values are shown. (D) Heatmap representation of RNA&#8208;seq <italic toggle="yes">z</italic>&#8208;score for TCGA 2015 UCologne SCLC data. The column represents 81 SCLC patient tumors, and the row represents LSD1i signature genes generated from (A). Genes captured for each signature from the TCGA samples were as follows (captured genes/total signature genes): 3426/3471 for NE signature; 1169/1179 for ML signature; 533/568 for LSD1i sensitivity signature; 90/94 for resistance signature. The NE&#8208;ML score was calculated by subtracting the NE score from the ML score for each tumor. Hypergeometric test <italic toggle="yes">P</italic>&#8208;values are shown.</p>
          </caption>
          <graphic ns1:href="MOL2-16-1309-g006" position="anchor" id="jats-graphic-7" />
        </fig>
        <p>Since sensitivity to LSD1 inhibition was associated with the presence or absence of expression of canonical neuroendocrine and mesenchymal markers in our previous analysis, we compared the GSK690 differentially expressed gene signature to an established gene coexpression network that delineates tumor heterogeneity observed in SCLC tumor samples as neuroendocrine (NE) and mesenchymal&#8208;like (ML) [<xref rid="mol213124-bib-0018" ref-type="bibr">18</xref>, <xref rid="mol213124-bib-0019" ref-type="bibr">19</xref>]. Aligning the LSD1 inhibition differential expression signature to genes defining the NE (<italic toggle="yes">n</italic>&#8201;=&#8201;1102) or ML (<italic toggle="yes">n</italic>&#8201;=&#8201;2663) coexpression networks [<xref rid="mol213124-bib-0019" ref-type="bibr">19</xref>], we found that sensitive cell lines significantly upregulated NE network genes, while resistant lines significantly upregulated ML network genes (Fig.&#8201;<xref rid="mol213124-fig-0003" ref-type="fig">3C</xref>). In addition, genes upregulated in LSD1 inhibitor sensitive cell lines significantly overlapped with NE network genes while genes upregulated in LSD1 inhibitor&#8208;resistant cell lines significantly overlapped with the ML network genes (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S4</xref>B). Overall, these data highlight the context specificity of GSK690 activity in neuroendocrine SCLC subtypes and explain the heterogeneous drug responses observed in SCLC cell lines.</p>
        <p>We next assessed the potential of the LSD1 sensitivity signature in identification of SCLC patients that might be sensitive or resistant to LSD1 inhibition. Using the differential gene expression signatures that stratify cell lines sensitive and resistant to LSD1 inhibitors (Fig.&#8201;<xref rid="mol213124-fig-0003" ref-type="fig">3A</xref>), TCGA 2015 UCologne SCLC patient dataset was analyzed. Patients with high expression of NE genes correlated with genes increased in expression in the LSD1 sensitivity signature score. Conversely, patients enriched in ML signature overlapped with LSD1 inhibitor resistance gene expression (Fig.&#8201;<xref rid="mol213124-fig-0003" ref-type="fig">3D</xref>). Thus, the LSD1 inhibitor gene expression signature defined distinct subsets of SCLC patients that are predicted to be either sensitive or resistant to LSD1 inhibitors.</p>
      </sec>
      <sec id="mol213124-sec-0014">
        <label>3.4</label>
        <title>Drug&#8208;tolerant cells with mesenchymal&#8208;like states emerge after LSD1 inhibitor treatment</title>
        <p>Small&#8208;cell lung cancer cell lines grow in floating cell aggregates; however, a subset of cell lines will grow attached to tissue culture plastic [<xref rid="mol213124-bib-0044" ref-type="bibr">44</xref>, <xref rid="mol213124-bib-0045" ref-type="bibr">45</xref>]. Cell lines which grow in suspension tend to express neuroendocrine markers while adherently growing cell lines are&#8201;enriched in mesenchymal biomarkers [<xref rid="mol213124-bib-0019" ref-type="bibr">19</xref>]. SCLC cells that persist after day 10 of 0.3&#8201;&#181;<sc>m</sc> GSK690 treatment show profound morphologic changes. NCI&#8208;H526 cells changed from loose floating aggregate to tightly adherent spheres (Fig.&#8201;<xref rid="mol213124-fig-0004" ref-type="fig">4A</xref>). COR&#8208;L88 cells changed morphologically and gained adherence to tissue culture&#8208;treated plates at day 12 of GSK690 treatment (Fig.&#8201;<xref rid="mol213124-fig-0004" ref-type="fig">4A</xref>).</p>
        <fig position="float" fig-type="Fig." id="mol213124-fig-0004">
          <label>Fig. 4</label>
          <caption>
            <p>LSD1 inhibitor treatment results in gene expression changes in axonal and EMT pathways (A) Microscope images of NCI&#8208;H526 and COR&#8208;L88 cell clusters (scale bar, 100&#8201;&#181;m) grown in tissue culture following treatment with DMSO or 0.3&#8201;&#181;<sc>m</sc> GSK690 for indicated times with <italic toggle="yes">n</italic>&#8201;=&#8201;3 independent experiments. (B) RNA&#8208;seq analysis of genes significantly altered (FDR &lt;&#8201;0.05, fold change &#8805;&#8201;2) in expression in GSK690&#8208;sensitive cell lines NCI&#8208;H69, NCI&#8208;H1417, NCI&#8208;H889, and COR&#8208;L88 and GSK690&#8208;insensitive cell lines NCI&#8208;H82 and NCI&#8208;H1694&#8208;treated with vehicle (DMSO) or 0.3&#8201;&#181;<sc>m</sc> GSK690 for 10&#8201;days, with <italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent replicates. (C) Venn diagrams reflecting overlap of genes significantly upregulated or downregulated by GSK690 treatment between SCLC cell lines. (D) Pathway analysis of genes altered in expression (FDR &lt;&#8201;0.05, fold change &#8805;&#8201;2) by GSK690 treatment utilizing MSigDB pathway databases. Top 10 enriched pathways are shown with the <italic toggle="yes">P</italic>&#8208;value cutoff of 0.05.</p>
          </caption>
          <graphic ns1:href="MOL2-16-1309-g002" position="anchor" id="jats-graphic-9" />
        </fig>
        <p>Since morphological changes are known to occur in SCLC cells that transition to a mesenchymal state [<xref rid="mol213124-bib-0046" ref-type="bibr">46</xref>], we assessed whether LSD1 inhibitor persister populations shift to a mesenchymal differentiation state. We performed bulk RNA&#8208;seq on four sensitive cell lines (NCI&#8208;H889, NCI&#8208;H1417, NCI&#8208;H69, and COR&#8208;L88) and two insensitive cell lines (NCI&#8208;H82 and NCI&#8208;H1694). At day 10 of GSK690 treatment, a larger number of genes show changes in all four sensitive cell lines, with the majority of genes showing upregulation (FDR &lt;&#8201;0.05, fold change &#8805;&#8201;2) (Fig.&#8201;<xref rid="mol213124-fig-0004" ref-type="fig">4B</xref>). Interestingly, only five genes and 43 genes were significantly altered after 10&#8201;days of GSK690 treatment in two GSK690&#8208;insensitive models, NCI&#8208;H82 and NCI&#8208;H1694, respectively (Fig.&#8201;<xref rid="mol213124-fig-0004" ref-type="fig">4B</xref>). Evaluation of common transcriptional changes occurring in sensitive models revealed only seven genes as consistently altered (FDR &lt;&#8201;0.05, fold change &#8805;&#8201;2) in expression at day 10 in all four cells lines (Fig.&#8201;<xref rid="mol213124-fig-0004" ref-type="fig">4C</xref>). However, the data showed more convergence at a pathway level with several common pathways identified showing consistent changes due to GSK690 treatment in the four sensitive cell lines. Pathways associated with genes upregulated by GSK690 treatment are enrichment in epithelial&#8211;mesenchymal transition pathway, TGF&#8208;beta signaling, NOTCH signaling, and focal adhesion&#8208;related signaling consistent with the observed changes in adhesion (Fig.&#8201;<xref rid="mol213124-fig-0004" ref-type="fig">4D</xref>, Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S4</xref>C). Conversely, pathways enriched in genes downregulated by GSK690 treatment did not show overlap between different cell lines and include various signaling pathways (Fig.&#8201;<xref rid="mol213124-fig-0004" ref-type="fig">4D</xref>, Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S4</xref>C).</p>
        <p>Changes in neuroendocrine and mesenchymal markers were also observed at the protein level in GSK690&#8208;sensitive cell models (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S6</xref>). COR&#8208;L88 cells showed the strongest shift into a mesenchymal&#8208;like state showing downregulation of neuroendocrine proteins NSE, GRP, NCAM, and CHGA and neuroendocrine transcription factors FOXA2, ASCL1, and SOX2. COR&#8208;L88 cells also showed strong upregulation of the mesenchymal protein VIM. Other GSK690&#8208;sensitive cell models showed only small changes in protein levels across our panel with GRP reduction and ZEB1 and CDH2 upregulation being the most consistent markers of response (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S6</xref>). We observed no consistent changes in the protein levels of any neuroendocrine and mesenchymal markers in GSK690&#8208;insensitive cell lines. Importantly, the extent of mesenchymal gene induction in GSK690&#8208;treated SCLC cells does appear comparatively lower relative to what we observed in mesenchymal&#8208;shifted NCI&#8208;H69V cells and thus may represent a &#8216;partial EMT&#8217; [<xref rid="mol213124-bib-0047" ref-type="bibr">47</xref>].</p>
      </sec>
      <sec id="mol213124-sec-0015">
        <label>3.5</label>
        <title>LSD1 inhibitor persister cells evolve from epigenetically distinct subpopulations</title>
        <p>To define the origin of mesenchymal&#8208;like persister cells, we conducted single cell RNA&#8208;seq analysis on NCI&#8208;H69 cells treated with DMSO or 0.3&#8201;&#956;<sc>m</sc> GSK690 for 21&#8201;days. Harmony [<xref rid="mol213124-bib-0031" ref-type="bibr">31</xref>] was applied to integrate DMSO and treatment groups so that gene expression within each single cell subpopulation can be directly compared with obtain subpopulation&#8208;specific differentially expressed (DE) genes after treatment (Fig.&#8201;<xref rid="mol213124-fig-0005" ref-type="fig">5A</xref>). To identify distinct cell subpopulations, unsupervised cell clustering was performed and five clusters were selected manually after visualization using uniform manifold approximation and projection (UMAP) (Fig.&#8201;<xref rid="mol213124-fig-0005" ref-type="fig">5B</xref> and Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S7</xref>A). Cell subpopulations in Clusters 0 and 3 were increased in 0.3&#8201;&#956;<sc>m</sc> GSK690&#8208;treated group relative to the DMSO group (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S7</xref>A). In contrast, cell subpopulations in Clusters 1 and 2 in DMSO group were reduced after 21&#8201;days of LSD1 inhibitor treatment (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S7</xref>A). There was no significant difference in the Cluster 4 cell subpopulation between DMSO and treated groups. Cluster 2 was identified as a neuroendocrine&#8208;like subpopulation, as neuroendocrine transcriptional factors GRP and ASCL1 were specifically upregulated in this subpopulation (Fig.&#8201;<xref rid="mol213124-fig-0005" ref-type="fig">5B</xref> and Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S8</xref>A). Both GRP expression and ASCL1 expression were strongly reduced in Cluster 2 after treatment (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S7</xref>B). In addition, the mean expression of neuroendocrine markers (NE score) including ASCL1, CHGA, GRP, INSM1, NCAM1, FOXA2, and SOX2 was significantly reduced in Cluster 2 after treatment (Fig.&#8201;<xref rid="mol213124-fig-0005" ref-type="fig">5C</xref>, left), suggesting cells in this cluster are losing NE features. On the other hand, the mean expression of 76 EMT marker genes from the Broad MSigDB Hallmark Signatures (EMT score) was upregulated in multiple cell clusters after treatment, but most significantly increased in Cluster 0 (Fig.&#8201;<xref rid="mol213124-fig-0005" ref-type="fig">5C</xref>, right). This observation is supported by the significant upregulation of EMT and lung cancer survival pathways in Cluster 0 after treatment (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S8</xref>B). Altogether, these results highlight the loss of NE cell subpopulation and the emergence of several transcriptionally distinct, mesenchymal&#8208;like populations in NCI&#8208;H69 cells resistant to LSD1 inhibitors.</p>
        <fig position="float" fig-type="Fig." id="mol213124-fig-0005">
          <label>Fig. 5</label>
          <caption>
            <p>Single cell RNA&#8208;seq reveals emergence of cell subpopulations enriched in EMT pathways following LSD1 inhibitor treatment (A) Uniform Manifold Approximation and Projection (UMAP) representation of pre&#8208; and post&#8208;Harmony integrated single cell RNA&#8208;seq data following treatment with vehicle (DMSO) or 0.3&#8201;&#956;<sc>m</sc> GSK690 for 21&#8201;days. (B) UMAP representation of cell clustering and GRP and ASCL1 expression violin plot in each cluster. (C) Mean expression of NE or ML gene sets in UMAP or as violin plots in each cluster (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent replicates). Two sample <italic toggle="yes">t</italic>&#8208;test <italic toggle="yes">P</italic>&#8208;values are shown.</p>
          </caption>
          <graphic ns1:href="MOL2-16-1309-g007" position="anchor" id="jats-graphic-11" />
        </fig>
        <p>In an attempt to assess the reversibility of the mesenchymal shift observed in LSD1 inhibitor persister cells, we performed drug washout experiments. After 14&#8201;days of GSK690 treatment in NCI&#8208;H526 and NCI&#8208;H69 cells, antiproliferative effects occurred concomitant with the upregulation of mesenchymal markers CDH2, SNA1, MYC, VIM, and ZEB1 and the downregulation of neuroendocrine markers GRP, ASCL1, and CHGA (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S9</xref>). After 7&#8201;days of drug washout, gene expression signatures recovered in both cell lines to levels similar to that observed in DMSO controls. Moreover, after 7&#8201;days of drug washout, cells regained sensitivity to LSD1 inhibition to a similar extent as untreated cell lines (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S9</xref>). These data suggest that the mesenchymal shift in SCLC cells treated with LSD1 inhibitors is reversible and caused by an &#8216;epi&#8208;stable&#8217; mesenchymal&#8208;like differentiation state.</p>
      </sec>
      <sec id="mol213124-sec-0016">
        <label>3.6</label>
        <title>LSD1 inhibitor resistance occurs through chromatin accessibility changes for genes associated with neuroendocrine&#8208; and mesenchymal&#8208;like programs</title>
        <p>We next sought to define the extent of epigenetic reprogramming in LSD1 inhibitor drug&#8208;tolerant cells by employing an assay for transposase&#8208;accessible chromatin using sequencing (ATAC&#8208;seq). ATAC&#8208;seq data in NCI&#8208;H69 cells treated with 0.3&#8201;&#956;<sc>m</sc> GSK690 for 21&#8201;days were highly reproducible between biological replicates and showed clear enrichment at specific genomic regions (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S10</xref>A). Consistent with observed changes in gene expression, differentially open or closed chromatin accessibility peaks were primarily identified at distal regulatory regions of genes after 21&#8201;days of GSK690 treatment compared with controls (Fig.&#8201;<xref rid="mol213124-fig-0006" ref-type="fig">6A</xref>, Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S10</xref>B). GREAT gene ontology analysis [<xref rid="mol213124-bib-0039" ref-type="bibr">39</xref>] for genes acquiring open chromatin accessibility peaks near regulatory regions suggests enrichment in pathways involved in mesenchyme morphogenesis and regulation of epithelial cell differentiation (Fig.&#8201;<xref rid="mol213124-fig-0006" ref-type="fig">6B</xref>). In contrast, genes that acquire closed chromatin do not show any significant pathway enrichment.</p>
        <fig position="float" fig-type="Fig." id="mol213124-fig-0006">
          <label>Fig. 6</label>
          <caption>
            <p>Chromatin accessibility changes for genes associated with neuroendocrine and mesenchymal expression signatures (A) ATAC&#8208;seq signal at differentially open or closed regions (FDR &lt;&#8201;1% and fold change &gt;&#8201;2.5) between vehicle (DMSO day 0 and day 21) or 0.3&#8201;&#956;<sc>m</sc> GSK690 (day 21) in NCI&#8208;H69 cells (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent replicates). (B) GO Biological Process using GREAT analysis with open genes associated with 0.3&#8201;&#956;<sc>m</sc> GSK690 treatment. (C) Heatmap representing TF <italic toggle="yes">z</italic>&#8208;scores of significantly open or closed TF DNA binding motifs (<italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent replicates). (D) Volcano plot showing the significantly open or closed TF DNA binding motifs (FDR &lt;&#8201;1% and difference in mean <italic toggle="yes">z</italic>&#8208;score &gt;&#8201;20) with 0.3&#8201;&#956;<sc>m</sc> GSK690 using chromVar analysis. (E) Growth curves of NCI&#8208;H69 cells treated with either 1&#8201;&#181;<sc>m</sc> LSD1 inhibitor GSK690, or 1&#8201;&#181;<sc>m</sc> TED&#8208;347, or combination of 1&#8201;&#181;<sc>m</sc> GSK690 with 1&#8201;&#181;<sc>m</sc> TED&#8208;347 for 21&#8201;days followed by 21&#8208;day drug washout (mean&#8201;&#177;&#8201;SD with <italic toggle="yes">n</italic>&#8201;=&#8201;3 biologically independent replicates). Two&#8208;way ANOVA multiple comparisons with *<italic toggle="yes">P</italic>&#8208;values &#8804;&#8201;0.001 between 1&#8201;&#181;<sc>m</sc> GSK690 and 1&#8201;&#181;<sc>m</sc> GSK690 plus 1&#8201;&#181;<sc>m</sc> TED&#8208;347 are shown.</p>
          </caption>
          <graphic ns1:href="MOL2-16-1309-g004" position="anchor" id="jats-graphic-13" />
        </fig>
        <p>To study the transcription factor programs regulating drug&#8208;resistant SCLC cells, we identified the transcription factor motifs represented in differentially accessible, closed or open, chromatin regions after GSK690 treatment (Fig.&#8201;<xref rid="mol213124-fig-0006" ref-type="fig">6C,D</xref>). We used <sc>chromvar</sc> [<xref rid="mol213124-bib-0040" ref-type="bibr">40</xref>], a package designed for inferring transcription factor activity from ATAC&#8208;seq based on chromatin accessibility levels at TF binding motifs genome&#8208;wide (Fig.&#8201;<xref rid="mol213124-fig-0006" ref-type="fig">6C,D</xref>). Our analysis demonstrated that NEUROD1/NEUROD2 and ASCL1 DNA binding motifs were significantly closed following GSK690 treatment. The DNA binding motif for TEAD4 is the only significantly opened region with the treatment (Fig.&#8201;<xref rid="mol213124-fig-0006" ref-type="fig">6C,D</xref>). TEAD4 is a downstream mediator of YAP1 activity, which has been previously identified as a possible phenotypic modulator in a subset of non&#8208;neuroendocrine SCLC cell lines [<xref rid="mol213124-bib-0048" ref-type="bibr">48</xref>]. A small molecule, TED&#8208;347, was recently discovered to demonstrate covalent engagement of cysteine to inhibit TEAD4&#183;YAP1 protein&#8211;protein interaction and block TEAD transcriptional activity [<xref rid="mol213124-bib-0049" ref-type="bibr">49</xref>]. We treated NCI&#8208;H69 cells with either LSD1 inhibitor GSK690 or combination with TED&#8208;347 for 21&#8201;days. Combination treatment with TED&#8208;347 significantly prevented the cell regrowth following the drug withdrawal for up to 21&#8201;days (Fig.&#8201;<xref rid="mol213124-fig-0006" ref-type="fig">6E</xref>). Thus, inhibiting TEAD transcriptional activity prevents the acquired resistance of SCLC in response to LSD1 inhibitors. These data indicate that mesenchymal&#8208;like drug tolerance in SCLC cell lines occurs through epigenetic reprogramming mediated through changes in transcription factor programs driven by oncogenic YAP signaling.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="mol213124-sec-0017">
      <label>4</label>
      <title>Discussion</title>
      <p>In this study, we have identified common features of intrinsic and acquired drug resistance to LSD1 inhibitors through epigenetic changes in SCLC neuroendocrine transcriptional programs. Epigenetic plasticity is known to contribute to the poor durability of responses of SCLC to current therapies as selection of mesenchymal enriched clones become enriched in refractory disease found in relapse [<xref rid="mol213124-bib-0050" ref-type="bibr">50</xref>, <xref rid="mol213124-bib-0051" ref-type="bibr">51</xref>]. Many SCLC cell lines analyzed in this study show either no response or only partial response to LSD1 inhibitors even after 21&#8201;days of treatment, suggesting many SCLC cell lines either have a preexisting drug&#8208;resistant population or are capable of transitioning to a drug&#8208;resistant state. Experimentally neuroendocrine SCLC cell lines can transition from neuroendocrine into mesenchymal phenotypes when treated with targeted or chemotherapies [<xref rid="mol213124-bib-0019" ref-type="bibr">19</xref>, <xref rid="mol213124-bib-0044" ref-type="bibr">44</xref>, <xref rid="mol213124-bib-0045" ref-type="bibr">45</xref>, <xref rid="mol213124-bib-0050" ref-type="bibr">50</xref>]. This observation is clinically relevant as SCLC tumors are often composed of epigenetically heterogeneous cells with either a neuroendocrine or a mesenchymal profile [<xref rid="mol213124-bib-0018" ref-type="bibr">18</xref>, <xref rid="mol213124-bib-0019" ref-type="bibr">19</xref>, <xref rid="mol213124-bib-0050" ref-type="bibr">50</xref>].</p>
      <p>Despite early literature suggesting LSD1 inhibitors would be broadly active in numerous cancers including colon, prostate, and breast cancer [<xref rid="mol213124-bib-0012" ref-type="bibr">12</xref>, <xref rid="mol213124-bib-0052" ref-type="bibr">52</xref>, <xref rid="mol213124-bib-0053" ref-type="bibr">53</xref>], the generation of more selective LSD1 inhibitors has clarified the extent of LSD1 inhibitor activity primarily in AML and SCLC [<xref rid="mol213124-bib-0005" ref-type="bibr">5</xref>, <xref rid="mol213124-bib-0054" ref-type="bibr">54</xref>]. One possible explanation for this discrepancy is suggested from the recent reports identifying noncatalytic mechanisms of action of current LSD1 inhibitors being explored in the clinic. Inhibition of the interaction of LSD1 with SNAG domain&#8208;containing proteins INSM1 or GFI1B impacts expression of key neuroendocrine lineage transcriptional regulators in SCLC including ASCL1 [<xref rid="mol213124-bib-0015" ref-type="bibr">15</xref>]. Recently, a specific inhibitor of LSD1 enzyme activity has been discovered, T&#8208;448 [<xref rid="mol213124-bib-0055" ref-type="bibr">55</xref>], which has minimal impact on the interaction of the LSD1&#8208;CoRest complex with SNAG domain transcription factors. In our studies, T&#8208;448 has no antiproliferative effect on NCI&#8208;H69 cells after 21&#8208;day treatment (Fig.&#8201;<xref rid="mol213124-sup-0001" ref-type="supplementary-material">S11</xref>), suggesting that the mechanism of action of LSD inhibitors occurs primarily through disruption of the interaction of LSD1 with SNAG domain transcription factors. Our data demonstrate that all cell lines sensitive to LSD1 inhibitors express either INSM1 or GFI1B; however, a subset of cell lines resistant to the drug also express these genes. Thus, the expression of these SNAG domain&#8208;containing proteins alone does not predict sensitivity to LSD1 inhibitors. Interestingly, LSD1 has been found to interact with the SNAG domain of SNAIL and implicated in the transcriptional repression of epithelial markers during EMT transition in breast cancer cells [<xref rid="mol213124-bib-0056" ref-type="bibr">56</xref>]. The role of LSD1 in the SNAG domain of targeted proteins appears to be context and lineage specific.</p>
      <p>Our results demonstrate that SCLC cells which have evolved non&#8208;neuroendocrine, mesenchymal&#8208;like transcriptional programs are resistant to LSD1 inhibition. These findings are consistent with Mohammad <italic toggle="yes">et&#8201;al</italic>., [<xref rid="mol213124-bib-0005" ref-type="bibr">5</xref>] who identified TGF&#8208;beta pathway signatures negatively correlate with LSD1 inhibitor sensitivity in SCLC. The TGF&#8208;beta pathway is known to regulate EMT pathways in cancer as well as in normal development [<xref rid="mol213124-bib-0046" ref-type="bibr">46</xref>]. In cell lines sensitive to LSD1 inhibitors, we did observe enrichment for TGF&#8208;beta pathway genes as well as genes involved in axonal and EMT pathways after LSD1 inhibitor treatment. Therefore, these data are potentially consistent with our observation that neuroendocrine and mesenchymal differentiation markers stratify sensitivity of SCLC cell lines to LSD1 inhibitors. Augert <italic toggle="yes">et&#8201;al</italic>. also identified heterogeneous responses to the LSD1 inhibitor ORY&#8208;1001 in a screen of SCLC patient&#8208;derived xenograft (PDX) models [<xref rid="mol213124-bib-0013" ref-type="bibr">13</xref>]. In their study, PDX models capable of NOTCH activation and concomitant ASCL1 downregulation were enriched in response to LSD1 inhibition. In gene expression studies following GSK690 treatment, we did observe induction of NOTCH pathway genes in COR&#8208;L88 and NCI&#8208;H1417 cells but not to the same extent in NCI&#8208;H69 or NCI&#8208;H889 cells. This suggests that NOTCH pathway&#8208;independent mechanisms of LSD1 inhibitor response exist in SCLC.</p>
      <p>This study highlights the remarkable plasticity of SCLC to evolve into drug&#8208;resistant mesenchymal&#8208;like states. Along these lines, we found expression of the neuroendocrine transcription factor ASCL1 was downregulated after GSK690 treatment in most models with the exception of NCI&#8208;H526 cells which shows a very low expression level of ASCL1 and is reported that the interaction between LSD1 and SNAG domain protein GFI1B plays a key role in this cell line [<xref rid="mol213124-bib-0015" ref-type="bibr">15</xref>]. The extent of mesenchymal gene induction in GSK690&#8208;treated SCLC cells does appear comparatively lower relative to what we observed in mesenchymal&#8208;shifted NCI&#8208;H69V cells and thus may represent a &#8216;partial EMT&#8217; [<xref rid="mol213124-bib-0047" ref-type="bibr">47</xref>]. In support of this model, drug washout experiments suggest these changes are &#8216;epi&#8208;stable&#8217; as cells revert to neuroendocrine phenotypes within 7&#8201;days of drug removal. Additionally, we found many SCLC cell lines analyzed in this study show only partial response to LSD1 inhibitors even after 21&#8201;days of treatment, suggesting many SCLC cell lines are capable of transitioning to a drug&#8208;resistant state. Single cell RNA&#8208;seq suggests that this resistant population likely represents an acquired drug&#8208;tolerant state represented by transcriptional reprogramming that is maintained under drug selection. Consistent with this finding, ATAC&#8208;seq data in NCI&#8208;H69 cells highlighted a shift in the utilization of transcription factors from ASCL1 to TEAD4 in drug&#8208;resistant cells. Interestingly, the expression of TEAD4 and downstream YAP and TAZ have recently been highlighted to represent a unique subtype of non&#8208;ASCL1&#8208;driven SCLC [<xref rid="mol213124-bib-0048" ref-type="bibr">48</xref>]. Our data suggest that inhibiting TEAD transcriptional activity may be an effective strategy to prevent the acquired resistance of SCLC in response to LSD1 inhibitors.</p>
      <p>A recent phase I study of GSK2879552 in relapsed or refractory SCLC found a disease control rate of 14% (four of 29 patients) [<xref rid="mol213124-bib-0057" ref-type="bibr">57</xref>]. High rates of adverse events, including thrombocytopenia and encephalopathy, lead to the termination of the study. Our data suggest that only a segment of SCLC patients, with a defined neuroendocrine differentiation state, will likely benefit from LSD1 inhibitors. In LSD1 inhibitor&#8208;treated patients, a mesenchymal&#8208;like resistant population is likely to persist. Thus, emphasis should focus on drug combination approaches that can sustain clinical responses by eliminating cells that maintain residual disease. Experimentally, it has been demonstrated that SCLC cells treated with chemotherapy [<xref rid="mol213124-bib-0050" ref-type="bibr">50</xref>] or radiotherapy [<xref rid="mol213124-bib-0058" ref-type="bibr">58</xref>] obtain mesenchymal characteristics that confer drug resistance. Thus, the efficacy of LSD1 inhibitors in SCLC patients heavily pretreated with chemotherapy will be an important consideration. The recent disclosures of additional LSD1 inhibitors, IMG&#8208;7289, INCB059872, and CC&#8208;90011, under clinical development for SCLC highlight the importance of clarifying the mechanism of action as well as further defining the clinical application of these drugs [<xref rid="mol213124-bib-0006" ref-type="bibr">6</xref>].</p>
    </sec>
    <sec sec-type="conclusions" id="mol213124-sec-0018">
      <label>5</label>
      <title>Conclusions</title>
      <p>We discovered that epigenetic plasticity contributes to heterogeneous responsiveness of SCLC to LSD1 inhibitors. Sensitivity to LSD1 inhibitors in SCLC is confined primarily to cells that express neuroendocrine transcriptional programs. Selection of a TEAD4&#8208;driven mesenchymal&#8208;like subpopulation is likely to present a barrier to effective single&#8208;agent responses in the clinic. Drug combinations targeting the YAP&#8208;TEAD pathways in combination with LSD1 inhibitors may be an effective strategy to target intrinsic and adaptive mesenchymal&#8208;like resistant populations and sustain effective clinical responses.</p>
    </sec>
    <sec sec-type="COI-statement" id="mol213124-sec-0020">
      <title>Conflict of interest</title>
      <p>WY, C&#8208;YC, SS, TX, MO, TN, JF, and TAP are employed by and hold stock in Pfizer, Inc. No potential conflicts of interests were disclosed by the other authors.</p>
    </sec>
    <sec id="mol213124-sec-0021">
      <title>Author contributions</title>
      <p>WY designed and executed experiments; collected, analyzed, and interpreted data and contributed to writing and editing the manuscript. C&#8208;YC performed bioinformatic analyses; analyzed and interpreted data; and contributed to writing the manuscript. TX performed bioinformatic analyses. MO executed experiments and analyzed data. TCN and JF executed and analyzed histopathology. ARU reviewed and provided input on the contents of the manuscript. SS designed the study, analyzed, and interpreted data and contributed to writing the manuscript. TAP designed the study and wrote the manuscript. All authors reviewed and approved the final manuscript.</p>
    </sec>
    <sec id="mol213124-sec-0022">
      <sec disp-level="2" id="mol213124-sec-0023">
        <title>Peer Review</title>
        <p>The peer review history for this article is available at <ext-link ns1:href="https://publons.com/publon/10.1002/1878-0261.13124" ext-link-type="uri">https://publons.com/publon/10.1002/1878&#8208;0261.13124</ext-link>.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material id="mol213124-sup-0001" position="float" content-type="local-data">
        <caption>
          <p>
<bold>Fig.&#8201;S1.</bold> Growth rates of NCI&#8208;H526 (A, left) and DMS114 (B, left) cells stably expressing either control shRNA or two independent shRNAs targeting LSD1 following 4, 7, or 14 days post&#8208;infection with lentiviral vector. Knockdown of LSD1 was assessed by western blot at day 4 post&#8208;infection in NCI&#8208;H526 (A, right) and DMS114 (B, right) cells. Two&#8208;way ANOVA multiple comparisons with p&#8208;values are shown. Lentiviral shRNA vectors pRSI12&#8208;U6&#8208;(sh)&#8208;UbiC&#8208;TagRFP&#8208;2A&#8208;Puro were purchased from Cellecta with targeting sequences for non&#8208;targeting (CAACAAGATGAAGAGCACCAA), LSD1 shRNA #1 (CCAACAATTAGAAGCACCTTA) and LSD1 shRNA #2 (AGGAAGGCTCTTCTAGCAATA). Each shRNA lentiviral expression construct was packaged with lentiviral packaging mix (Thermo Scientific) in 293T cells according to manufacturer&#8217;s instructions. Cell growth was monitored by CellTiter&#8208;Glo Luminescent Cell Viability Assay (Promega) at day 7 and day 14 from experimental triplicates.</p>
          <p>
<bold>Fig.&#8201;S2.</bold> Structures and profile of GSK690 (R)&#8208;4&#8208;(5&#8208;(pyrrolidin&#8208;3&#8208;ylmethoxy)&#8208;2&#8208;(p&#8208;tolyl)pyridin&#8208;3&#8208;yl)benzonitrile and OG&#8208;86 (1S,2R)&#8208;N&#8208;((2&#8208;methoxypyridin&#8208;3&#8208;yl)methyl)&#8208;2&#8208;phenylcyclopropan&#8208;1&#8208;amine compounds based off publicly available data.</p>
          <p>
<bold>Fig.&#8201;S3.</bold> Long&#8208;term proliferation assays for NCI&#8208;H1417 (A), NCI&#8208;H187 (B), NCI&#8208;H889 (C), and DMS&#8208;114 (D) cells treated with vehicle (DMSO), 0.3 &#181;M or 1.0 &#181;M GSK690, or 0.3 &#181;M or 1.0 &#181;M OG&#8208;86. (E) Cell cycle analysis of NCI&#8208;H526, COR&#8208;L88, and NCI&#8208;H1417 cells after 7 days of treatment with DMSO or indicated concentrations of GSK690. (F) Cell cycle analysis by propidium iodide staining in COR&#8208;L88 cells treated with DMSO, 0.3 &#181;M, or 1 &#181;M GSK690 for 14 days. Cell number was calculated from experimental triplicates by cell counting at indicated time points. Two&#8208;way ANOVA multiple comparisons with p&#8208;values are shown.</p>
          <p>
<bold>Fig.&#8201;S4.</bold> Gene expression (Log2) and copy number of MYC, MYCN, and MYCL in GSK690 sensitive and resistant SCLC cell lines.</p>
          <p>
<bold>Fig.&#8201;S5.</bold> (A) Principal component analysis of cell line gene expression derived from CCLE cell line data showing segregation of GSK690 sensitive models (green) and resistant models (red) on PC1 vs. PC2. (B) Venn diagram showing overlap of DE gene signature from Figure&#8201;3A with previously published NE or ML signature genes [1]. (C) Pathway analysis of genes altered in expression (FDR &lt; 0.05, fold change &#8805;&#8201;2) by GSK690 treatment utilizing MSigDB pathway databases. Top 10 enriched pathways are shown with the p&#8208;value cutoff of 0.05.</p>
          <p>
<bold>Fig.&#8201;S6.</bold> Western Blot analysis of neuroendocrine and mesenchymal protein levels using indicated antibodies in SCLC cells lines treated with DMSO or 0.3 &#181;M GSK690 for 14 days.</p>
          <p>
<bold>Fig.&#8201;S7.</bold> (A) Left: cluster number selection within UMAP using resolution = 0.15. To optimize single cell clustering, we tuned the &#8220;resolution&#8221; parameter in Seurat, and selected resolution = 0.15 by visual inspection and the presence of robust differential markers between clusters. Right: cell number change in each cluster depicted as percentage of total cells in each cluster before and after GSK690 treatment. (B) Expression of ASCL1 or GRP in cluster 2 in UMAP or as violin plots following treatment with vehicle (DMSO) or 0.3 &#956;M GSK690 for 21 days.</p>
          <p>
<bold>Fig.&#8201;S8.</bold> (A) Top 10 uniquely expressed genes in each single cell RNA&#8208;seq cluster. The cluster specific genes were identified by performing DE analyses between each cluster with all the rest of clusters. DE cutoff is FDR &lt; 5% and logFC &gt;&#8201;0.25. (B) For differential pathway analysis, a hypergeometric test with FDR correction was applied to cluster specific differential genes using the MSigDB data base. NE (8 genes) or EMT (76 genes) gene score were calculated as the mean expression value of the detected gene sets in each single cell, and two sample t&#8208;test was performed to calculate the significance between DMSO and treatment. Pathways analysis showed top 10 up&#8208;regulated pathways within each cluster following treatment of 0.3 &#956;M GSK690 for 21 days. P&#8208;value cutoff = 0.05. Cluster 3 and 4 did not have any significant enrichment.</p>
          <p>
<bold>Fig.&#8201;S9.</bold> Cell viability and gene expression of neuroendocrine and mesenchymal markers in NCI&#8208;H526 and NCI&#8208;H69 cells pre&#8208;treated with 0.3 &#181;M GSK690 for 14 days and following 7&#8208;day washout.</p>
          <p>
<bold>Fig.&#8201;S10.</bold> (A) Representative ATAC&#8208;seq profiles of biological replicates from day 0, day 21 DMSO or 0.3 &#181;M GSK690 treatment. (B) Percentage of ATAC&#8208;seq peaks in cells treated with GSK690, separated into promoter (&lt;&#177;3 kb transcription start site [TSS]) and distal regions (&gt;&#177;3 kb TSS).</p>
          <p>
<bold>Fig.&#8201;S11.</bold> Long&#8208;term proliferation assay for NCI&#8208;H69 cells treated with T&#8208;448 with a dose&#8208;range up to 1.8 uM for 21 days.</p>
        </caption>
        <media ns1:href="MOL2-16-1309-s001.docx">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="mol213124-sec-0019">
      <title>Acknowledgements</title>
      <p>The authors thank Jill Hallin, Ying Ding, and Mike Greig for their efforts in the early phase of this project. We also thank Sabrina Li for her contribution in doing experiments to address the reviewers&#8217; questions. We thank Elizabeth McMillan for reviewing and providing input to the manuscript. We are grateful to Robert Hollingsworth for the support and review of the manuscript. All sources of funding for the research reported here are supported by Pfizer, Inc.</p>
    </ack>
    <sec sec-type="data-availability" id="mol213124-sec-0024">
      <title>Data accessibility</title>
      <p>All data generated and/or analyzed during this study are available within this manuscript or as Supplementary Information and from the corresponding authors.</p>
    </sec>
    <ref-list content-type="cited-references" id="mol213124-bibl-0001">
      <title>References</title>
      <ref id="mol213124-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0001">
<string-name>
<surname>George</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Jang</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Cun</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ozretic</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Kong</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Leenders</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Fernandez&#8208;Cuesta</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bosco</surname>
<given-names>G</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2015</year>) <article-title>Comprehensive genomic profiles of small cell lung cancer</article-title>. <source>Nature</source>
<volume>524</volume>, <fpage>47</fpage>&#8211;<lpage>53</lpage>.<pub-id pub-id-type="pmid">26168399</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0002">
<string-name>
<surname>Otterson</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Hodgson</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Vokes</surname>
<given-names>EE</given-names>
</string-name> &amp; <collab collab-type="authors">Cancer and Leukemia Group B</collab>
(<year>2010</year>) <article-title>Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)</article-title>. <source>J Thorac Oncol</source>
<volume>5</volume>, <fpage>1644</fpage>&#8211;<lpage>1648</lpage>.<pub-id pub-id-type="pmid">20871263</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0003">
<string-name>
<surname>Lenhart</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Kirov</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Desilva</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lei</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schweizer</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Purandare</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ross&#8208;Macdonald</surname>
<given-names>P</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2015</year>) <article-title>Sensitivity of small cell lung cancer to BET inhibition is mediated by regulation of ASCL1 gene expression</article-title>. <source>Mol Cancer Ther</source>
<volume>14</volume>, <fpage>2167</fpage>&#8211;<lpage>2174</lpage>.<pub-id pub-id-type="pmid">26253517</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0004">
<string-name>
<surname>Poirier</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Gardner</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Connis</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Moreira</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>de Stanchina</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Hann</surname>
<given-names>CL</given-names>
</string-name> &amp; <string-name>
<surname>Rudin</surname>
<given-names>CM</given-names>
</string-name> (<year>2015</year>) <article-title>DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2</article-title>. <source>Oncogene</source>
<volume>34</volume>, <fpage>5869</fpage>&#8211;<lpage>5878</lpage>.<pub-id pub-id-type="pmid">25746006</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0005">
<string-name>
<surname>Mohammad</surname>
<given-names>HP</given-names>
</string-name>, <string-name>
<surname>Smitheman</surname>
<given-names>KN</given-names>
</string-name>, <string-name>
<surname>Kamat</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Soong</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Federowicz</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Van Aller</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Schneck</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Carson</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Butticello</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2015</year>) <article-title>A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC</article-title>. <source>Cancer Cell</source>
<volume>28</volume>, <fpage>57</fpage>&#8211;<lpage>69</lpage>.<pub-id pub-id-type="pmid">26175415</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0006">
<string-name>
<surname>Fang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>G</given-names>
</string-name> &amp; <string-name>
<surname>Yu</surname>
<given-names>B</given-names>
</string-name> (<year>2019</year>) <article-title>LSD1/KDM1A inhibitors in clinical trials: advances and prospects</article-title>. <source>J Hematol Oncol</source>
<volume>12</volume>, <fpage>129</fpage>.<pub-id pub-id-type="pmid">31801559</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0007">
<string-name>
<surname>Hakimi</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Bochar</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Chenoweth</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lane</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Mandel</surname>
<given-names>G</given-names>
</string-name> &amp; <string-name>
<surname>Shiekhattar</surname>
<given-names>R</given-names>
</string-name> (<year>2002</year>) <article-title>A core&#8208;BRAF35 complex containing histone deacetylase mediates repression of neuronal&#8208;specific genes</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>99</volume>, <fpage>7420</fpage>&#8211;<lpage>7425</lpage>.<pub-id pub-id-type="pmid">12032298</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0008">
<string-name>
<surname>Ceballos&#8208;Chavez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rivero</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Garcia&#8208;Gutierrez</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rodriguez&#8208;Paredes</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Garcia&#8208;Dominguez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bhattacharya</surname>
<given-names>S</given-names>
</string-name> &amp; <string-name>
<surname>Reyes</surname>
<given-names>JC</given-names>
</string-name> (<year>2012</year>) <article-title>Control of neuronal differentiation by sumoylation of BRAF35, a subunit of the LSD1&#8208;CoREST histone demethylase complex</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>109</volume>, <fpage>8085</fpage>&#8211;<lpage>8090</lpage>.<pub-id pub-id-type="pmid">22570500</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0009">
<string-name>
<surname>Iwase</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Januma</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Miyamoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shono</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Honda</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Yanagisawa</surname>
<given-names>J</given-names>
</string-name> &amp; <string-name>
<surname>Baba</surname>
<given-names>T</given-names>
</string-name> (<year>2004</year>) <article-title>Characterization of BHC80 in BRAF&#8208;HDAC complex, involved in neuron&#8208;specific gene repression</article-title>. <source>Biochem Biophys Res Commun</source>
<volume>322</volume>, <fpage>601</fpage>&#8211;<lpage>608</lpage>.<pub-id pub-id-type="pmid">15325272</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0010">
<string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lan</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Matson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mulligan</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Whetstine</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Casero</surname>
<given-names>RA</given-names>
</string-name> &amp; <string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name> (<year>2004</year>) <article-title>Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</article-title>. <source>Cell</source>
<volume>119</volume>, <fpage>941</fpage>&#8211;<lpage>953</lpage>.<pub-id pub-id-type="pmid">15620353</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0011">
<string-name>
<surname>Laurent</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Ruitu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Murn</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hempel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ferrao</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Xiang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Garcia</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>F</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2015</year>) <article-title>A specific LSD1/KDM1A isoform regulates neuronal differentiation through H3K9 demethylation</article-title>. <source>Mol Cell</source>
<volume>57</volume>, <fpage>957</fpage>&#8211;<lpage>970</lpage>.<pub-id pub-id-type="pmid">25684206</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0012">
<string-name>
<surname>Metzger</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Wissmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yin</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Schneider</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Gunther</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Buettner</surname>
<given-names>R</given-names>
</string-name> &amp; <string-name>
<surname>Schule</surname>
<given-names>R</given-names>
</string-name> (<year>2005</year>) <article-title>LSD1 demethylates repressive histone marks to promote androgen&#8208;receptor&#8208;dependent transcription</article-title>. <source>Nature</source>
<volume>437</volume>, <fpage>436</fpage>&#8211;<lpage>439</lpage>.<pub-id pub-id-type="pmid">16079795</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0013">
<string-name>
<surname>Augert</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Eastwood</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ibrahim</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Grunblatt</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Basom</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Liggitt</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Eaton</surname>
<given-names>KD</given-names>
</string-name>, <string-name>
<surname>Martins</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Poirier</surname>
<given-names>JT</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2019</year>) <article-title>Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition</article-title>. <source>Sci Signal</source>
<volume>12</volume>, <elocation-id>eaau2922</elocation-id>.<pub-id pub-id-type="pmid">30723171</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0014">
<string-name>
<surname>Vinyard</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Siegenfeld</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Waterbury</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Freedy</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Gosavi</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kwan</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Senzer</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Doench</surname>
<given-names>JG</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2019</year>) <article-title>CRISPR&#8208;suppressor scanning reveals a nonenzymatic role of LSD1 in AML</article-title>. <source>Nat Chem Biol</source>
<volume>15</volume>, <fpage>529</fpage>&#8211;<lpage>539</lpage>.<pub-id pub-id-type="pmid">30992567</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0015">
<string-name>
<surname>Takagi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ishikawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mizutani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Iwasaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Matsumoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kamada</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nomura</surname>
<given-names>T</given-names>
</string-name> &amp; <string-name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</string-name> (<year>2017</year>) <article-title>LSD1 inhibitor T&#8208;3775440 inhibits SCLC cell proliferation by disrupting LSD1 interactions with SNAG domain proteins INSM1 and GFI1B</article-title>. <source>Cancer Res</source>
<volume>77</volume>, <fpage>4652</fpage>&#8211;<lpage>4662</lpage>.<pub-id pub-id-type="pmid">28667074</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0016">
<string-name>
<surname>Rudin</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Poirier</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Byers</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Dive</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dowlati</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Heymach</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Lehman</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>MacPherson</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2019</year>) <article-title>Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data</article-title>. <source>Nat Rev Cancer</source>
<volume>19</volume>, <fpage>289</fpage>&#8211;<lpage>297</lpage>.<pub-id pub-id-type="pmid">30926931</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0017">
<string-name>
<surname>Rudin</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Poirier</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Byers</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Dive</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dowlati</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>George</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Heymach</surname>
<given-names>JV</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Lehman</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>MacPherson</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2019</year>) <article-title>Author correction: molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data</article-title>. <source>Nat Rev Cancer</source>
<volume>19</volume>, <fpage>415</fpage>.<pub-id pub-id-type="pmid">31175338</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0018">
<string-name>
<surname>Wooten</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Groves</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Tyson</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Albert</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lopez</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Sage</surname>
<given-names>J</given-names>
</string-name> &amp; <string-name>
<surname>Quaranta</surname>
<given-names>V</given-names>
</string-name> (<year>2019</year>) <article-title>Systems&#8208;level network modeling of Small Cell Lung Cancer subtypes identifies master regulators and destabilizers</article-title>. <source>PLoS Comput Biol</source>
<volume>15</volume>, <elocation-id>e1007343</elocation-id>.<pub-id pub-id-type="pmid">31671086</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0019">
<string-name>
<surname>Udyavar</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Wooten</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Hoeksema</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bansal</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Califano</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Estrada</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Schnell</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Irish</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Massion</surname>
<given-names>PP</given-names>
</string-name> &amp; <string-name>
<surname>Quaranta</surname>
<given-names>V</given-names>
</string-name> (<year>2017</year>) <article-title>Novel hybrid phenotype revealed in small cell lung cancer by a transcription factor network model that can explain tumor heterogeneity</article-title>. <source>Cancer Res</source>
<volume>77</volume>, <fpage>1063</fpage>&#8211;<lpage>1074</lpage>.<pub-id pub-id-type="pmid">27932399</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="miscellaneous" id="mol213124-cit-0020">
<string-name>
<surname>Dhanak</surname>
<given-names>D</given-names>
</string-name> (<year>2013</year>) <article-title>Drugging the cancer epigenome</article-title>. <italic toggle="yes">Proceedings of the 104th annual meeting of the American association for cancer research</italic>.</mixed-citation>
      </ref>
      <ref id="mol213124-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0021">
<string-name>
<surname>Guibourt</surname>
<given-names>NOA</given-names>
</string-name> &amp; <string-name>
<surname>Laria</surname>
<given-names>JPC</given-names>
</string-name> (<year>2010</year>) <article-title>Phenylcyclopropylamine derivatives and their medical use</article-title>. <source>PCT Int Appl</source> WO 2010084160 A1 20100729.</mixed-citation>
      </ref>
      <ref id="mol213124-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0022">
<string-name>
<surname>Li</surname>
<given-names>B</given-names>
</string-name> &amp; <string-name>
<surname>Dewey</surname>
<given-names>CN</given-names>
</string-name> (<year>2011</year>) <article-title>RSEM: accurate transcript quantification from RNA&#8208;Seq data with or without a reference genome</article-title>. <source>BMC Bioinformatics</source>
<volume>12</volume>, <fpage>323</fpage>.<pub-id pub-id-type="pmid">21816040</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0023">
<string-name>
<surname>Anders</surname>
<given-names>S</given-names>
</string-name> &amp; <string-name>
<surname>Huber</surname>
<given-names>W</given-names>
</string-name> (<year>2010</year>) <article-title>Differential expression analysis for sequence count data</article-title>. <source>Genome Biol</source>
<volume>11</volume>, <fpage>R106</fpage>.<pub-id pub-id-type="pmid">20979621</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0024">
<string-name>
<surname>Barretina</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Caponigro</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Stransky</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Venkatesan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Margolin</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Lehar</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Kryukov</surname>
<given-names>GV</given-names>
</string-name>, <string-name>
<surname>Sonkin</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2012</year>) <article-title>The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity</article-title>. <source>Nature</source>
<volume>483</volume>, <fpage>603</fpage>&#8211;<lpage>607</lpage>.<pub-id pub-id-type="pmid">22460905</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0025">
<string-name>
<surname>Ritchie</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Phipson</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Law</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>W</given-names>
</string-name> &amp; <string-name>
<surname>Smyth</surname>
<given-names>GK</given-names>
</string-name> (<year>2015</year>) <article-title>limma powers differential expression analyses for RNA&#8208;sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source>
<volume>43</volume>, <elocation-id>e47</elocation-id>.<pub-id pub-id-type="pmid">25605792</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0026">
<string-name>
<surname>Gu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Eils</surname>
<given-names>R</given-names>
</string-name> &amp; <string-name>
<surname>Schlesner</surname>
<given-names>M</given-names>
</string-name> (<year>2016</year>) <article-title>Complex heatmaps reveal patterns and correlations in multidimensional genomic data</article-title>. <source>Bioinformatics</source>
<volume>32</volume>, <fpage>2847</fpage>&#8211;<lpage>2849</lpage>.<pub-id pub-id-type="pmid">27207943</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0027">
<string-name>
<surname>Subramanian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tamayo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mootha</surname>
<given-names>VK</given-names>
</string-name>, <string-name>
<surname>Mukherjee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ebert</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Gillette</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Paulovich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pomeroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Golub</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Lander</surname>
<given-names>ES</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2005</year>) <article-title>Gene set enrichment analysis: a knowledge&#8208;based approach for interpreting genome&#8208;wide expression profiles</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>102</volume>, <fpage>15545</fpage>&#8211;<lpage>15550</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0028">
<string-name>
<surname>Langfelder</surname>
<given-names>P</given-names>
</string-name> &amp; <string-name>
<surname>Horvath</surname>
<given-names>S</given-names>
</string-name> (<year>2008</year>) <article-title>WGCNA: an R package for weighted correlation network analysis</article-title>. <source>BMC Bioinformatics</source>
<volume>9</volume>, <fpage>559</fpage>.<pub-id pub-id-type="pmid">19114008</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0029">
<string-name>
<surname>Stuart</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Butler</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hoffman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hafemeister</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Papalexi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mauck</surname>
<given-names>WM</given-names>
<suffix>3rd</suffix>
</string-name>, <string-name>
<surname>Hao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Stoeckius</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Smibert</surname>
<given-names>P</given-names>
</string-name> &amp; <string-name>
<surname>Satija</surname>
<given-names>R</given-names>
</string-name> (<year>2019</year>) <article-title>Comprehensive integration of single&#8208;cell data</article-title>. <source>Cell</source>
<volume>177</volume>, <fpage>1888</fpage>&#8211;<lpage>1902.e21</lpage>.<pub-id pub-id-type="pmid">31178118</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0030">
<string-name>
<surname>Hafemeister</surname>
<given-names>C</given-names>
</string-name> &amp; <string-name>
<surname>Satija</surname>
<given-names>R</given-names>
</string-name> (<year>2019</year>) <article-title>Normalization and variance stabilization of single&#8208;cell RNA&#8208;seq data using regularized negative binomial regression</article-title>. <source>Genome Biol</source>
<volume>20</volume>, <fpage>296</fpage>.<pub-id pub-id-type="pmid">31870423</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0031">
<string-name>
<surname>Korsunsky</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Millard</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Slowikowski</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Baglaenko</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Brenner</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Loh</surname>
<given-names>PR</given-names>
</string-name> &amp; <string-name>
<surname>Raychaudhuri</surname>
<given-names>S</given-names>
</string-name> (<year>2019</year>) <article-title>Fast, sensitive and accurate integration of single&#8208;cell data with Harmony</article-title>. <source>Nat Methods</source>
<volume>16</volume>, <fpage>1289</fpage>&#8211;<lpage>1296</lpage>.<pub-id pub-id-type="pmid">31740819</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0032">
<string-name>
<surname>Becht</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>McInnes</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Healy</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dutertre</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Kwok</surname>
<given-names>IWH</given-names>
</string-name>, <string-name>
<surname>Ng</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Ginhoux</surname>
<given-names>F</given-names>
</string-name> &amp; <string-name>
<surname>Newell</surname>
<given-names>EW</given-names>
</string-name> (<year>2018</year>) <article-title>Dimensionality reduction for visualizing single&#8208;cell data using UMAP</article-title>. <source>Nat Biotechnol</source>
<volume>37</volume>, <fpage>38</fpage>&#8211;<lpage>44</lpage>.</mixed-citation>
      </ref>
      <ref id="mol213124-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0033">
<string-name>
<surname>Langmead</surname>
<given-names>B</given-names>
</string-name> &amp; <string-name>
<surname>Salzberg</surname>
<given-names>SL</given-names>
</string-name> (<year>2012</year>) <article-title>Fast gapped&#8208;read alignment with Bowtie 2</article-title>. <source>Nat Methods</source>
<volume>9</volume>, <fpage>357</fpage>&#8211;<lpage>359</lpage>.<pub-id pub-id-type="pmid">22388286</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0034">
<string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Meyer</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Eeckhoute</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Bernstein</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Nusbaum</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Myers</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2008</year>) <article-title>Model&#8208;based analysis of ChIP&#8208;Seq (MACS)</article-title>. <source>Genome Biol</source>
<volume>9</volume>, <fpage>R137</fpage>.<pub-id pub-id-type="pmid">18798982</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0035">
<string-name>
<surname>Kent</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Zweig</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Barber</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hinrichs</surname>
<given-names>AS</given-names>
</string-name> &amp; <string-name>
<surname>Karolchik</surname>
<given-names>D</given-names>
</string-name> (<year>2010</year>) <article-title>BigWig and BigBed: enabling browsing of large distributed datasets</article-title>. <source>Bioinformatics</source>
<volume>26</volume>, <fpage>2204</fpage>&#8211;<lpage>2207</lpage>.<pub-id pub-id-type="pmid">20639541</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0036">
<string-name>
<surname>Robinson</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Thorvaldsdottir</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Winckler</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Guttman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lander</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Getz</surname>
<given-names>G</given-names>
</string-name> &amp; <string-name>
<surname>Mesirov</surname>
<given-names>JP</given-names>
</string-name> (<year>2011</year>) <article-title>Integrative genomics viewer</article-title>. <source>Nat Biotechnol</source>
<volume>29</volume>, <fpage>24</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">21221095</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0037">
<string-name>
<surname>Ramirez</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Dundar</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Diehl</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Gruning</surname>
<given-names>BA</given-names>
</string-name> &amp; <string-name>
<surname>Manke</surname>
<given-names>T</given-names>
</string-name> (<year>2014</year>) <article-title>deepTools: a flexible platform for exploring deep&#8208;sequencing data</article-title>. <source>Nucleic Acids Res</source>
<volume>42</volume>, <fpage>W187</fpage>&#8211;<lpage>W191</lpage>.<pub-id pub-id-type="pmid">24799436</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0038">
<string-name>
<surname>Love</surname>
<given-names>MI</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>W</given-names>
</string-name> &amp; <string-name>
<surname>Anders</surname>
<given-names>S</given-names>
</string-name> (<year>2014</year>) <article-title>Moderated estimation of fold change and dispersion for RNA&#8208;seq data with DESeq2</article-title>. <source>Genome Biol</source>
<volume>15</volume>, <fpage>550</fpage>.<pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0039">
<string-name>
<surname>McLean</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Bristor</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hiller</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Clarke</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Schaar</surname>
<given-names>BT</given-names>
</string-name>, <string-name>
<surname>Lowe</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Wenger</surname>
<given-names>AM</given-names>
</string-name> &amp; <string-name>
<surname>Bejerano</surname>
<given-names>G</given-names>
</string-name> (<year>2010</year>) <article-title>GREAT improves functional interpretation of cis&#8208;regulatory regions</article-title>. <source>Nat Biotechnol</source>
<volume>28</volume>, <fpage>495</fpage>&#8211;<lpage>501</lpage>.<pub-id pub-id-type="pmid">20436461</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0040">
<string-name>
<surname>Schep</surname>
<given-names>AN</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Buenrostro</surname>
<given-names>JD</given-names>
</string-name> &amp; <string-name>
<surname>Greenleaf</surname>
<given-names>WJ</given-names>
</string-name> (<year>2017</year>) <article-title>chromVAR: inferring transcription&#8208;factor&#8208;associated accessibility from single&#8208;cell epigenomic data</article-title>. <source>Nat Methods</source>
<volume>14</volume>, <fpage>975</fpage>&#8211;<lpage>978</lpage>.<pub-id pub-id-type="pmid">28825706</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0041">
        <label>41</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0041">
<string-name>
<surname>Morgan</surname>
<given-names>MA</given-names>
</string-name> &amp; <string-name>
<surname>Shilatifard</surname>
<given-names>A</given-names>
</string-name> (<year>2015</year>) <article-title>Chromatin signatures of cancer</article-title>. <source>Genes Dev</source>
<volume>29</volume>, <fpage>238</fpage>&#8211;<lpage>249</lpage>.<pub-id pub-id-type="pmid">25644600</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0042">
        <label>42</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0042">
<collab collab-type="authors">Clinical Lung Cancer Genome, P.</collab>
&amp; <collab collab-type="authors">Network Genomic, M.</collab>
(<year>2013</year>) <article-title>A genomics&#8208;based classification of human lung tumors</article-title>. <source>Sci Transl Med</source>
<volume>5</volume>, <fpage>209ra153</fpage>.</mixed-citation>
      </ref>
      <ref id="mol213124-bib-0043">
        <label>43</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0043">
<string-name>
<surname>Khan</surname>
<given-names>MZ</given-names>
</string-name>, <string-name>
<surname>Freshney</surname>
<given-names>RI</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Merry</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Plumb</surname>
<given-names>JA</given-names>
</string-name> &amp; <string-name>
<surname>McNicol</surname>
<given-names>AM</given-names>
</string-name> (<year>1991</year>) <article-title>Identification and characterisation in&#8201;vitro of cells with a non&#8208;SCLC cell&#8208;like phenotype derived from a continuous SCLC cell line</article-title>. <source>Anticancer Res</source>
<volume>11</volume>, <fpage>1687</fpage>&#8211;<lpage>1695</lpage>.<pub-id pub-id-type="pmid">1662924</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0044">
        <label>44</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0044">
<string-name>
<surname>Carney</surname>
<given-names>DN</given-names>
</string-name>, <string-name>
<surname>Gazdar</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Bepler</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Guccion</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Marangos</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Moody</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Zweig</surname>
<given-names>MH</given-names>
</string-name> &amp; <string-name>
<surname>Minna</surname>
<given-names>JD</given-names>
</string-name> (<year>1985</year>) <article-title>Establishment and identification of small cell lung cancer cell lines having classic and variant features</article-title>. <source>Cancer Res</source>
<volume>45</volume>, <fpage>2913</fpage>&#8211;<lpage>2923</lpage>.<pub-id pub-id-type="pmid">2985257</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0045">
        <label>45</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0045">
<string-name>
<surname>Gazdar</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Carney</surname>
<given-names>DN</given-names>
</string-name>, <string-name>
<surname>Nau</surname>
<given-names>MM</given-names>
</string-name> &amp; <string-name>
<surname>Minna</surname>
<given-names>JD</given-names>
</string-name> (<year>1985</year>) <article-title>Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties</article-title>. <source>Cancer Res</source>
<volume>45</volume>, <fpage>2924</fpage>&#8211;<lpage>2930</lpage>.<pub-id pub-id-type="pmid">2985258</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0046">
        <label>46</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0046">
<string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lamouille</surname>
<given-names>S</given-names>
</string-name> &amp; <string-name>
<surname>Derynck</surname>
<given-names>R</given-names>
</string-name> (<year>2009</year>) <article-title>TGF&#8208;beta&#8208;induced epithelial to mesenchymal transition</article-title>. <source>Cell Res</source>
<volume>19</volume>, <fpage>156</fpage>&#8211;<lpage>172</lpage>.<pub-id pub-id-type="pmid">19153598</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0047">
        <label>47</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0047">
<string-name>
<surname>Jolly</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Boareto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ben&#8208;Jacob</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Onuchic</surname>
<given-names>JN</given-names>
</string-name> &amp; <string-name>
<surname>Levine</surname>
<given-names>H</given-names>
</string-name> (<year>2015</year>) <article-title>Implications of the hybrid epithelial/mesenchymal phenotype in metastasis</article-title>. <source>Front Oncol</source>
<volume>5</volume>, <fpage>155</fpage>.<pub-id pub-id-type="pmid">26258068</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0048">
        <label>48</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0048">
<string-name>
<surname>Horie</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ohshima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>HI</given-names>
</string-name> &amp; <string-name>
<surname>Nagase</surname>
<given-names>T</given-names>
</string-name> (<year>2016</year>) <article-title>YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer</article-title>. <source>Cancer Sci</source>
<volume>107</volume>, <fpage>1755</fpage>&#8211;<lpage>1766</lpage>.<pub-id pub-id-type="pmid">27627196</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0049">
        <label>49</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0049">
<string-name>
<surname>Bum&#8208;Erdene</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gonzalez&#8208;Gutierrez</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ghozayel</surname>
<given-names>MK</given-names>
</string-name>, <string-name>
<surname>Si</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Shannon</surname>
<given-names>HE</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Corson</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Pollok</surname>
<given-names>KE</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2019</year>) <article-title>Small&#8208;molecule covalent modification of conserved cysteine leads to allosteric inhibition of the TEADYap protein&#8208;protein interaction</article-title>. <source>Cell Chem Biol</source>
<volume>26</volume>, <fpage>378</fpage>&#8211;<lpage>389 e13</lpage>.<pub-id pub-id-type="pmid">30581134</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0050">
        <label>50</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0050">
<string-name>
<surname>Krohn</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ahrens</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yalcin</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Plones</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wehrle</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Taromi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wollner</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Follo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Brabletz</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mani</surname>
<given-names>SA</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2014</year>) <article-title>Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial&#8208;Mesenchymal Transition (EMT) and DNA methylation changes</article-title>. <source>PLoS One</source>
<volume>9</volume>, <elocation-id>e100249</elocation-id>.<pub-id pub-id-type="pmid">24959847</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0051">
        <label>51</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0051">
<string-name>
<surname>Brambilla</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Moro</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gazzeri</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brichon</surname>
<given-names>PY</given-names>
</string-name>, <string-name>
<surname>Nagy&#8208;Mignotte</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Morel</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Jacrot</surname>
<given-names>M</given-names>
</string-name> &amp; <string-name>
<surname>Brambilla</surname>
<given-names>C</given-names>
</string-name> (<year>1991</year>) <article-title>Cytotoxic chemotherapy induces cell differentiation in small&#8208;cell lung carcinoma</article-title>. <source>J Clin Oncol</source>
<volume>9</volume>, <fpage>50</fpage>&#8211;<lpage>61</lpage>.<pub-id pub-id-type="pmid">1702146</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0052">
        <label>52</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0052">
<string-name>
<surname>Huang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Stewart</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Baylin</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Marton</surname>
<given-names>LJ</given-names>
</string-name>, <string-name>
<surname>Perkins</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Woster</surname>
<given-names>PM</given-names>
</string-name> &amp; <string-name>
<surname>Casero</surname>
<given-names>RA</given-names>
<suffix>Jr</suffix>
</string-name> (<year>2009</year>) <article-title>Novel oligoamine analogues inhibit lysine&#8208;specific demethylase 1 and induce reexpression of epigenetically silenced genes</article-title>. <source>Clin Cancer Res</source>
<volume>15</volume>, <fpage>7217</fpage>&#8211;<lpage>7228</lpage>.<pub-id pub-id-type="pmid">19934284</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0053">
        <label>53</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0053">
<string-name>
<surname>Lim</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Janzer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schule</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Buettner</surname>
<given-names>R</given-names>
</string-name> &amp; <string-name>
<surname>Kirfel</surname>
<given-names>J</given-names>
</string-name> (<year>2010</year>) <article-title>Lysine&#8208;specific demethylase 1 (LSD1) is highly expressed in ER&#8208;negative breast cancers and a biomarker predicting aggressive biology</article-title>. <source>Carcinogenesis</source>
<volume>31</volume>, <fpage>512</fpage>&#8211;<lpage>520</lpage>.<pub-id pub-id-type="pmid">20042638</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0054">
        <label>54</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0054">
<string-name>
<surname>McGrath</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Williamson</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Balasubramanian</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Odate</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Arora</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hatton</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Magnuson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Stokoe</surname>
<given-names>D</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2016</year>) <article-title>Pharmacological inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypes</article-title>. <source>Cancer Res</source>
<volume>76</volume>, <fpage>1975</fpage>&#8211;<lpage>1988</lpage>.<pub-id pub-id-type="pmid">26837761</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0055">
        <label>55</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0055">
<string-name>
<surname>Matsuda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Baba</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Oki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Morimoto</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Toyofuku</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Igaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kamada</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Iwasaki</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Matsumiya</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hibino</surname>
<given-names>R</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2019</year>) <article-title>T&#8208;448, a specific inhibitor of LSD1 enzyme activity, improves learning function without causing thrombocytopenia in mice</article-title>. <source>Neuropsychopharmacology</source>
<volume>44</volume>, <fpage>1505</fpage>&#8211;<lpage>1512</lpage>.<pub-id pub-id-type="pmid">30580376</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0056">
        <label>56</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0056">
<string-name>
<surname>Lin</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ponn</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Law</surname>
<given-names>BK</given-names>
</string-name> &amp; <string-name>
<surname>Lu</surname>
<given-names>J</given-names>
</string-name> (<year>2010</year>) <article-title>Requirement of the histone demethylase LSD1 in Snai1&#8208;mediated transcriptional repression during epithelial&#8208;mesenchymal transition</article-title>. <source>Oncogene</source>
<volume>29</volume>, <fpage>4896</fpage>&#8211;<lpage>4904</lpage>.<pub-id pub-id-type="pmid">20562920</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0057">
        <label>57</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0057">
<string-name>
<surname>Bauer</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Besse</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Martinez&#8208;Marti</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Trigo</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Garrido</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ferron&#8208;Brady</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Collingwood</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#8201;al</italic>. (<year>2019</year>) <article-title>Phase I, open&#8208;label, dose&#8208;escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC</article-title>. <source>J Thorac Oncol</source>
<volume>14</volume>, <fpage>1828</fpage>&#8211;<lpage>1838</lpage>.<pub-id pub-id-type="pmid">31260835</pub-id></mixed-citation>
      </ref>
      <ref id="mol213124-bib-0058">
        <label>58</label>
        <mixed-citation publication-type="journal" id="mol213124-cit-0058">
<string-name>
<surname>Meredith</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Bryant</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Babur</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Riddell</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Behrouzi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>KJ</given-names>
</string-name> &amp; <string-name>
<surname>White</surname>
<given-names>A</given-names>
</string-name> (<year>2016</year>) <article-title>Irradiation decreases the neuroendocrine biomarker pro&#8208;opiomelanocortin in small cell lung cancer cells in&#8201;vitro and in&#8201;vivo</article-title>. <source>PLoS One</source>
<volume>11</volume>, <elocation-id>e0148404</elocation-id>.<pub-id pub-id-type="pmid">26848743</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>